OA16387A - Pharmaceutical composition, methods for treating and uses thereof. - Google Patents
Pharmaceutical composition, methods for treating and uses thereof. Download PDFInfo
- Publication number
- OA16387A OA16387A OA1201300165 OA16387A OA 16387 A OA16387 A OA 16387A OA 1201300165 OA1201300165 OA 1201300165 OA 16387 A OA16387 A OA 16387A
- Authority
- OA
- OAPI
- Prior art keywords
- insulin
- diabètes
- treating
- group
- preventing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 80
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 627
- 102000004877 Insulin Human genes 0.000 claims abstract description 348
- 108090001061 Insulin Proteins 0.000 claims abstract description 348
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 161
- 239000003112 inhibitor Substances 0.000 claims abstract description 158
- 101710040674 SLC5A2 Proteins 0.000 claims abstract description 155
- 102100016749 SLC5A2 Human genes 0.000 claims abstract description 155
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 16
- 208000008466 Metabolic Disease Diseases 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims description 161
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 160
- 239000000203 mixture Substances 0.000 claims description 116
- 210000004369 Blood Anatomy 0.000 claims description 93
- 239000008280 blood Substances 0.000 claims description 93
- 108010092217 Long-Acting Insulin Proteins 0.000 claims description 49
- 102000016261 Long-Acting Insulin Human genes 0.000 claims description 49
- 235000020828 fasting Nutrition 0.000 claims description 41
- 239000004026 insulin derivative Substances 0.000 claims description 39
- 201000010099 disease Diseases 0.000 claims description 36
- 238000002560 therapeutic procedure Methods 0.000 claims description 33
- 230000001771 impaired Effects 0.000 claims description 32
- 210000002381 Plasma Anatomy 0.000 claims description 29
- 208000008589 Obesity Diseases 0.000 claims description 26
- 235000020824 obesity Nutrition 0.000 claims description 26
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 24
- 210000000577 Adipose Tissue Anatomy 0.000 claims description 20
- 230000037396 body weight Effects 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- -1 (R)-tetrahydrofuran-3-yloxy Chemical group 0.000 claims description 16
- 230000000291 postprandial Effects 0.000 claims description 16
- 206010021036 Hyponatraemia Diseases 0.000 claims description 13
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 13
- 206010020993 Hypoglycaemia Diseases 0.000 claims description 12
- 206010033307 Overweight Diseases 0.000 claims description 12
- 201000001431 hyperuricemia Diseases 0.000 claims description 12
- 235000020825 overweight Nutrition 0.000 claims description 12
- 208000000913 Kidney Calculi Diseases 0.000 claims description 11
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 11
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 10
- 206010054805 Macroangiopathy Diseases 0.000 claims description 10
- 230000003451 hyperinsulinaemic Effects 0.000 claims description 10
- 201000008980 hyperinsulinism Diseases 0.000 claims description 10
- 230000002218 hypoglycaemic Effects 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 230000035945 sensitivity Effects 0.000 claims description 9
- 210000001519 tissues Anatomy 0.000 claims description 9
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 8
- 206010065941 Central obesity Diseases 0.000 claims description 8
- 150000001555 benzenes Chemical class 0.000 claims description 8
- 206010038932 Retinopathy Diseases 0.000 claims description 7
- 206010038923 Retinopathy Diseases 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 7
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrugs Drugs 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 206010056559 Graft infection Diseases 0.000 claims description 5
- 206010061255 Ischaemia Diseases 0.000 claims description 5
- 208000001083 Kidney Disease Diseases 0.000 claims description 5
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 5
- 206010029331 Neuropathy peripheral Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 201000003883 cystic fibrosis Diseases 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 210000002216 Heart Anatomy 0.000 claims description 4
- 206010029149 Nephropathy Diseases 0.000 claims description 4
- 206010029151 Nephropathy Diseases 0.000 claims description 4
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000010874 syndrome Diseases 0.000 claims description 4
- 206010007554 Cardiac failure Diseases 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000005846 Cardiomyopathy Diseases 0.000 claims description 2
- 208000008960 Diabetic Foot Diseases 0.000 claims description 2
- 206010019280 Heart failure Diseases 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- 201000008031 cardiomyopathy Diseases 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 200000000008 restenosis Diseases 0.000 claims description 2
- 230000033764 rhythmic process Effects 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 85
- COCFEDIXXNGUNL-RFKWWTKHSA-N Glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 64
- 108010057186 Insulin Glargine Proteins 0.000 description 58
- 229960002869 Insulin Glargine Drugs 0.000 description 52
- 230000035492 administration Effects 0.000 description 52
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 43
- 229960003105 Metformin Drugs 0.000 description 40
- 108010026951 Short-Acting Insulin Proteins 0.000 description 34
- 239000003472 antidiabetic agent Substances 0.000 description 33
- 230000002354 daily Effects 0.000 description 31
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 30
- 229960005095 Pioglitazone Drugs 0.000 description 30
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 26
- 229960002397 Linagliptin Drugs 0.000 description 26
- 239000002552 dosage form Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 238000009097 single-agent therapy Methods 0.000 description 22
- 241000700159 Rattus Species 0.000 description 19
- 239000007924 injection Substances 0.000 description 18
- 206010012601 Diabetes mellitus Diseases 0.000 description 17
- 238000002347 injection Methods 0.000 description 16
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N Levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 13
- 150000004677 hydrates Chemical class 0.000 description 13
- 239000007943 implant Substances 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 230000001225 therapeutic Effects 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WNRQPCUGRUFHED-DETKDSODSA-N Humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 9
- 230000003247 decreasing Effects 0.000 description 9
- 108010065920 Insulin Lispro Proteins 0.000 description 8
- 229960002068 Insulin Lispro Drugs 0.000 description 8
- 210000003734 Kidney Anatomy 0.000 description 8
- 229940060975 Lantus Drugs 0.000 description 8
- 229940102988 Levemir Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 229960001052 Streptozocin Drugs 0.000 description 7
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 6
- 229940116269 Uric Acid Drugs 0.000 description 6
- 208000005735 Water Intoxication Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004634 feeding behavior Effects 0.000 description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 6
- 108010050259 insulin degludec Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002035 prolonged Effects 0.000 description 6
- 231100000486 side effect Toxicity 0.000 description 6
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 5
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 5
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108010089308 Insulin Detemir Proteins 0.000 description 5
- 208000001280 Prediabetic State Diseases 0.000 description 5
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 5
- 229960003834 dapagliflozin Drugs 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- QLXKHBNJTPICNF-QMCAAQAGSA-N ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=CC=CC=C1CC1=CC=C(OC)C=C1 QLXKHBNJTPICNF-QMCAAQAGSA-N 0.000 description 5
- 229960004225 insulin degludec Drugs 0.000 description 5
- 229960003948 insulin detemir Drugs 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 201000009104 prediabetes syndrome Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 150000001467 thiazolidinediones Chemical class 0.000 description 5
- BUXGTLNOWLNUKF-SOVHRIKKSA-N (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-[(4-methoxyphenyl)methyl]thiophen-3-yl]oxyoxane-3,4,5-triol Chemical compound C1=CC(OC)=CC=C1CC1=C(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=CS1 BUXGTLNOWLNUKF-SOVHRIKKSA-N 0.000 description 4
- AHFWIQIYAXSLBA-RQXATKFSSA-N (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 4
- VWVKUNOPTJGDOB-BDHVOXNPSA-N (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol Chemical compound C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 VWVKUNOPTJGDOB-BDHVOXNPSA-N 0.000 description 4
- 229950002400 Atigliflozin Drugs 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 4
- 229960001381 Glipizide Drugs 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 210000001624 Hip Anatomy 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- VOMXSOIBEJBQNF-UTTRGDHVSA-N NovoRapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 4
- 210000002700 Urine Anatomy 0.000 description 4
- 230000001058 adult Effects 0.000 description 4
- 229960001713 canagliflozin Drugs 0.000 description 4
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 4
- 230000000271 cardiovascular Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229960004346 glimepiride Drugs 0.000 description 4
- 229950000991 ipragliflozin Drugs 0.000 description 4
- 230000002503 metabolic Effects 0.000 description 4
- 230000000069 prophylaxis Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 229950006667 tofogliflozin Drugs 0.000 description 4
- 238000007492 two-way ANOVA Methods 0.000 description 4
- 230000003442 weekly Effects 0.000 description 4
- GSINGUMRKGRYJP-VZWAGXQNSA-N (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxane-3,4,5-triol Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- RCHHVVGSTHAVPF-ZPHPLDECSA-N Apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 3
- LEMUFSYUPGXXCM-JNEQYSBXSA-N Caninsulin Chemical group [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 3
- 208000008787 Cardiovascular Disease Diseases 0.000 description 3
- 208000004981 Coronary Disease Diseases 0.000 description 3
- 229960003468 Gliquidone Drugs 0.000 description 3
- LLJFMFZYVVLQKT-UHFFFAOYSA-N Gliquidone Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- 108009000020 Glucose Homeostasis Proteins 0.000 description 3
- 108010041872 Islet amyloid polypeptide Proteins 0.000 description 3
- 102000036849 Islet amyloid polypeptide Human genes 0.000 description 3
- 210000004153 Islets of Langerhans Anatomy 0.000 description 3
- 108010081368 Isophane Insulin Proteins 0.000 description 3
- 102000005237 Isophane Insulin Human genes 0.000 description 3
- 210000001503 Joints Anatomy 0.000 description 3
- 102100008175 MGAM Human genes 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N Nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 3
- 229960000698 Nateglinide Drugs 0.000 description 3
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N Pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 3
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 3
- 101710040724 SLC5A11 Proteins 0.000 description 3
- 102100020034 SLC5A11 Human genes 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 229940058933 biguanide antimalarials Drugs 0.000 description 3
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 201000008739 coronary artery disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000021271 drinking Nutrition 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000003203 everyday Effects 0.000 description 3
- 230000014101 glucose homeostasis Effects 0.000 description 3
- 230000002641 glycemic Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 2
- RMTYNAPTNBJHQI-LLDVTBCESA-N 1-[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 2
- YAJCHEVQCOHZDC-QMMNLEPNSA-N Actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 2
- 102000003852 Autoantibodies Human genes 0.000 description 2
- 108090000206 Autoantibodies Proteins 0.000 description 2
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 2
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 2
- 206010061835 Diabetic nephropathy Diseases 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 210000001508 Eye Anatomy 0.000 description 2
- 229960000346 Gliclazide Drugs 0.000 description 2
- BOVGTQGAOIONJV-UHFFFAOYSA-N Gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 2
- 229960003236 Glisoxepide Drugs 0.000 description 2
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N Glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010018634 Gouty arthritis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010073961 Insulin Aspart Proteins 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 229960004329 Metformin hydrochloride Drugs 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003178 anti-diabetic Effects 0.000 description 2
- 230000002238 attenuated Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001610 euglycemic Effects 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 229960001764 glibornuride Drugs 0.000 description 2
- 230000035780 glucosuria Effects 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 201000005569 gout Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229960004717 insulin aspart Drugs 0.000 description 2
- 229960000696 insulin glulisine Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001110 miglitol Drugs 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960003611 pramlintide Drugs 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000002485 urinary Effects 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- JSYGLDMGERSRPC-FQUUOJAGSA-N (2S,4S)-4-fluoro-1-[2-[[(1R,3S)-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1[C@@H](F)C[C@@H](C#N)N1C(=O)CN[C@H]1C[C@@H](CN2N=CN=C2)CC1 JSYGLDMGERSRPC-FQUUOJAGSA-N 0.000 description 1
- DXXHHEGZUCEQCJ-UHFFFAOYSA-N (4-chlorophenyl) ethaneperoxoate Chemical compound CC(=O)OOC1=CC=C(Cl)C=C1 DXXHHEGZUCEQCJ-UHFFFAOYSA-N 0.000 description 1
- GUYMHFIHHOEFOA-ZCPGHIKRSA-N (4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one Chemical compound N1([C@H]2CN3CCC=4C=C(C(=CC=4[C@@H]3C[C@@H]2N)OC)OC)C[C@@H](CF)CC1=O GUYMHFIHHOEFOA-ZCPGHIKRSA-N 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N Alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 229940112930 Apidra Drugs 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000000476 Body Water Anatomy 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N Buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 229950003594 Carmegliptin Drugs 0.000 description 1
- 210000001188 Cartilage, Articular Anatomy 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- QGJUIPDUBHWZPV-YQBUGCKMSA-N DB07465 Chemical compound C([C@@H](C1)C2)[C@@H](C3)C[C@@]1(O)C[C@]23[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-YQBUGCKMSA-N 0.000 description 1
- 229950010300 Denagliptin Drugs 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 210000003722 Extracellular Fluid Anatomy 0.000 description 1
- 229940012151 Exubera Drugs 0.000 description 1
- 108010043222 Exubera Proteins 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 102100015189 GAD2 Human genes 0.000 description 1
- 101710009965 GAD2 Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229940038661 Humalog Drugs 0.000 description 1
- 229940084776 Humulin N Drugs 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229950002240 Isophane insulin Drugs 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010024855 Loss of consciousness Diseases 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229950009585 Melogliptin Drugs 0.000 description 1
- 210000000110 Microvilli Anatomy 0.000 description 1
- WPGGHFDDFPHPOB-BBWFWOEESA-N Mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 description 1
- 229940112879 NovoLog Drugs 0.000 description 1
- 229940103453 Novolin Drugs 0.000 description 1
- 229940098815 Novolin N Drugs 0.000 description 1
- 102100009127 PTPN22 Human genes 0.000 description 1
- 101710018431 PTPN22 Proteins 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N Phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 Phenformin Drugs 0.000 description 1
- IOUVKUPGCMBWBT-GHRYLNIYSA-N Phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 1
- 206010036067 Polydipsia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101710040671 SLC5A1 Proteins 0.000 description 1
- 102100016744 SLC5A1 Human genes 0.000 description 1
- 101710040722 SLC5A10 Proteins 0.000 description 1
- 101710040666 SLC5A4 Proteins 0.000 description 1
- 102100016759 SLC5A4 Human genes 0.000 description 1
- 229960004937 Saxagliptin Drugs 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 229950000378 Sergliflozin etabonate Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 210000004304 Subcutaneous Tissue Anatomy 0.000 description 1
- 229940099093 Symlin Drugs 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 108010061168 Ultralente Insulin Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102000004248 Zinc Transporter 8 Human genes 0.000 description 1
- 108090000702 Zinc Transporter 8 Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002058 anti-hyperglycaemic Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 description 1
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940000425 combination drugs Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N isocyanate Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- 229940006445 isophane insulin Drugs 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 230000000422 nocturnal Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000019139 phlorizin Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036514 plasma sodium concentration Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- 229960004457 pramlintide acetate Drugs 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229950011516 remogliflozin etabonate Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M sodium;7,9-dihydro-3H-purin-1-ide-2,6,8-trione Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000009095 third-line therapy Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 229940100888 zinc compounds Drugs 0.000 description 1
Abstract
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Description
Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
Technical Field ofthe Invention
The invention relates to a pharmaceutical composition comprising an SGLT2-inhibitor and an insulin as described hereinafter which is suitable in the treatment or prévention of one or more conditions selected from type 1 diabètes mellitus, type 2 diabètes mellitus, impaired glucose tolérance, impaired fasting blood glucose and hyperglycemia inter alia,
Furthermore the invention relates to methods
- for treating diabètes mellitus;
- for treating diabètes mellitus, where treatment with insulin îs required;
- for treating type 1 diabètes mellitus;
- for treating, preventing or reducing the risk of hypoglycemia;
- for preventing, slowing progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus;
- for preventing, slowing progression of, delaying, or treating a metabolic disorder;
- for improving glycémie control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c;
- for preventing, slowing, delaying or reversing progression from impaired glucose tolérance, impaired fasting blood glucose, insulin résistance and/or from metabolic syndrome to type 2 diabètes mellitus;
- for reducing body weight and/or body fat or preventing or attenuating an increase in body weight and/or body fat or facilitating a réduction in body weight and/or body fat;
- for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat;
- maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin résistance,
- for preventing, slowing progression of, delaying, or treating new onset diabètes after transplantation (NODAT) and/or post-transplant metabolic syndrome (PTMS);
- for preventing, delaying, or reducing NODAT and/or PTMS associated complications including micro- and macrovascular diseases and events, graft rejection, infection, and death;
- for treating hyperuricemia and hyperuricemia associated conditions;
- for treating or preventing kidney stones;
- for treating hyponatremia;
- for preventing, slowing progression of, delaying, or treating diabètes related to cystic fibrosis;
-2in patients in need thereof characterized in that an SGLT2 inhibitor and an insulin is administered in combination or alternation.
In addition the présent invention relates to the use of an SGLT2 inhibitor for the manufacture of a médicament for use in a method as described hereinbefore and hereinafter.
In addition, the présent invention relates to the use of an insulin for the manufacture of a médicament for use in a method as described hereinbefore and hereinafter.
The invention also relates to a pharmaceutical composition according to this invention for use in a method as described hereinbefore and hereinafter.
The invention also relates to a use of a pharmaceutical composition according to this invention for the manufacture of a médicament for use in a method as described hereinbefore and hereinafter.
Background ofthe Invention
Type 1 diabètes mellitus (Type 1 diabètes), also called insulin dépendent diabètes mellitus or juvénile diabètes, is a form of diabètes mellitus that results from autoimmune destruction of insulin-producing beta cells of the pancréas. The subséquent lack of insulin leads to increased blood glucose concentrations and increased urinary glucose excrétion. The classical symptoms are polyuria, polydipsia, polyphagia, and weight loss. Type 1 diabètes may be fatal unless treated with insulin. Complications may be associated with both hypoglycémie and hyperglycémie states. Serious hypoglycemia may lead to seizures or épisodes of unconsciousness requireing emergency treatment Uncontrolled hyperglycemia and insufficient insulin may lead to severe ketoacidosis which could be fatal. Hyperglycaemia per se might also in the short term lead to tiredness and Visual disturbances and can also resuit in long term damage to organs such as eyes, kidneys and joints. Subcutaneous injections are the most common method of administering insulin although inhaled insulin, as well as oral formulations, are being tested in clinical trials. Rapid acting insulin analogs hâve been developed which are more readily absorbed from the injection site and therefore act faster than rapid human insulin injected subcutaneously, intended to supply the bolus level of insulin needed after a meal. Other insulin analogs - so called long acting insulins (for example glargine insulin, detemir insulin) - are available which are released slowly over a period of time, for example 8 to 24 hours, intended to supply the basal level of insulin for the day.
-3Type 2 diabètes is an increasingly prévalent disease that due to a high frequency of complications associated with a réduction in life expectancy. Because of diabetes-associated microvascular complications, type 2 diabètes is currently the most frequent cause of adultonset loss of vision, rénal failure, and amputations in the industrialized world. In addition, the presence of type 2 diabètes is associated with a two to five fold increase in cardiovascular disease risk.
After long duration of disease, most patients with type 2 diabètes will eventually fait on oral therapy and become insulin dépendent with the necessîty for daily injections and multiple daily glucose measurements.
The UKPDS (United Kingdom Prospective Diabètes Study) demonstrated that intensive treatment with metformin, sulfonylureas or insulin resulted in only a limited improvement of glycémie control (différence in HbA1c -0.9%) as compared to conventional treatment. In addition, even in patients within the intensive treatment arm glycémie control deteriorated significantly over time and this was attributed to détérioration of beta-cell function. Of importance however, despite this détérioration of beta-cell function, was that intensive glycaemic treatment was associated with microvascular benefits in the short term (6 years) and macro-mascular benefits in the long term (15 years). Similar phenomenon has also been demonstrated in patients with type 1 diabètes mellitus, e.g. in the diabètes control and complications trial (DCCT) where a différence in the médian HbA1c (-1.9%) between the conventional therapy and intensive therapy group during 6.5 years of study, led to signifïcant relative risk réductions for microvascular complications whereas macrovascular benefits was noted 11 years after the DCCT, e.g. as reported in the EDIC (Epidemiology of Diabètes Interventions and Complications) study, where a relative HbA1c réduction by 10% in one patient compared to another was associated with a hazard ratio of 0.80 for cardiovascular complications. Despite such convincing long term effects of glycaemic management many patients with type 2 diabètes or type 1 diabètes remain inadequately treated, partly because of limitations in long term efficacy, tolerability and dosing inconvenience of existing antihyperglycemic thérapies.
Oral antidiabetic drugs conventionally used in therapy (such as e.g. first- or second-line, and/or mono- or (initial or add-on) combination therapy) include, without being restricted thereto, metformin, sulphonylureas, thiazolidinediones, glinides and α-glucosidase inhibitors.
The high incidence of therapeutic failure might be a major contributor to the high rate of longterm hyperglycemia-associated complications or chronic damages (including micro- and
-4macrovascular complications such as e.g. diabetic nephrophathy, retinopathy or neuropathy, or cardiovascular complications) in patients with type 2 diabètes or type 1 diabètes.
Therefore, there is an unmet medical need for methods, médicaments and pharmaceutical compositions with a good efficacy with regard to glycémie control, with regard to diseasemodifying properties and with regard to réduction of cardiovascular morbidity and mortality while at the same time showing an improved safety profile.
SGLT2 inhibitors inhibitors represent a novel class of agents that are being developed for the treatment or improvement in glycémie control in patients with type 2 diabètes.
Glucopyranosyl-substituted benzene dérivative are described in the prior art as SGLT2 inhibitors, for example in WO 01/27128, WO 03/099836, WO 2005/092877, WO 2006/034489, WO 2006/064033, WO 2006/117359, WO 2006/117360, WO 2007/025943, WO 2007/028814, WO 2007/031548, WO 2007/093610, WO 2007/128749, WO 2008/049923, WO 2008/055870, WO 2008/055940. The glucopyranosyl-substituted benzene dérivatives are proposed as inducers of urinary sugar excrétion and as médicaments in the treatment of diabètes.
Rénal filtration and reuptake of glucose contributes, among other mechanisms, to the steady state plasma glucose concentration and can therefore serve as an antidiabetic target. Reuptake of filtered glucose across épithélial cells of the kidney proceeds via sodiumdependent glucose cotransporters (SGLTs) located in the brush-border membranes in the tubuli along the sodium gradient. There are at least 3 SGLT isoforms that differ in their expression pattern as well as in their physico-chemical properties. SGLT2 is exclusively expressed in the kidney, whereas SGLT1 is expressed additionally in other tissues like intestine, colon, skeletal and cardiac muscle. SGLT3 has been found to be a glucose sensor in interstitial cells of the intestine without any transport function. Potentially, other related, but not yet characterized genes, may contribute further to rénal glucose reuptake. Under normoglycemia, glucose is completely reabsorbed by SGLTs in the kidney, whereas the reuptake capacity of the kidney is saturated at glucose concentrations higher than 10mM, resulting in glucosuria (hence the notion “diabètes mellitus). This threshold concentration can be decreased by SGLT2-inhibition. It has been shown in experiments with the SGLT inhibitor phlorizin that SGLT-inhibition will partially inhibit the reuptake of glucose from the glomerular filtrate into the blood leading to a decrease in blood glucose concentrations and to glucosuria.
Aim of the présent invention
-5The aim of the présent invention is to provide a pharmaceutical composition and method for preventing, slowing progression of, delaying or treating a metabolic disorder, in particular of diabètes mellitus and complications of diabètes mellitus.
Another aim of the présent invention is to provide a pharmaceutical composition and method for treating patients with type 1 diabètes mellitus.
A further aim of the présent invention is to provide a pharmaceutical composition and method for improving glycémie control in a patient in need thereof, in particular in patients with type 1 or type 2 diabètes mellitus.
Another aim of the présent invention is to provide a pharmaceutical composition and method for improving glycémie control in a patient.
Another aim of the présent invention is to provide a pharmaceutical composition and method for prolonging the duration of efficacy of an insulin administered to a patient.
Another aim of the présent invention is to provide a pharmaceutical composition and method for reducing the required insulin dose in a patient.
Another aim of the présent invention is to provide a pharmaceutical composition and method for preventing, slowing or delaying progression from împaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), insulin résistance and/or metabolic syndrome to type 2 diabètes mellitus.
Yet another aim of the présent invention is to provide a pharmaceutical composition and method for preventing, slowing progression of, delaying or treating of a condition or disorder from the group consisting of complications of diabètes mellitus, in particular type 1 or type 2 diabètes mellitus.
A further aim of the présent invention is to provide a pharmaceutical composition and method for reducing the weight or preventing or attenuating an increase of the weight in a patient in need thereof.
Another aim of the présent invention is to provide a new pharmaceutical composition with a high efficacy for the treatment of metabolic disorders, in particular of diabètes mellitus, impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), and/or
-6hyperglycemia, which has good to very good pharmacological and/or pharmacokinetic and/or physicochemical properties.
Further aims of the présent invention become apparent to the one skilled in the art by description hereinbefore and in the following and by the examples.
Summary of the Invention
Within the scope of the présent invention it has now surprisingly been found that a combination of a SGLT2 inhibitor and an insulïn leads to a higher blood glucose lowering compared with a treatment using the insulin or the SGLT2 inhibitor alone. Thus in order to achieve a certain level of baseline blood glucose the dose of the insulin may be reduced by using a combination of a SGLT2 inhibitor and an insulin. Furthermore it has surprisingly been found that an administration of a SGLT2 inhibitor in a time period after the administration of an insulin prolonges the lowering of the blood glucose compared with an administration of the insulin alone.
Therefore a combination of a SGLT2 inhibitor and an insulin can advantageously be used for preventing, slowing progression of, delaying or treating a metabolic disorder, in particular for improving glycémie control in patients. This opens up new therapeutic possibilities in the treatment and prévention of type 1 diabètes mellitus, type 2 diabètes mellitus, complications of diabètes mellitus and of neighboring disease states.
Therefore, in a first aspect the présent invention provides a pharmaceutical composition comprising (a) an SGLT2 inhibitor, and (b) an insulin.
According to another aspect of the invention, there is provided a method for treating diabètes mellitus in a patient characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
According to another aspect of the invention, there is provided a method for treating diabètes mellitus in a patient where treatment with insulin is requried characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
-7According to another aspect of the invention, there is provided a method for treating type 1 diabètes mellitus in a patient characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient
According to another aspect of the invention, there is provided a method for treating, preventing or reducing the risk of hypoglycemia in a patient characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
According to another aspect ofthe invention, there is provided a method for preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis, in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient. In particular one or more aspects of diabetic nephropathy such as hyperperfusion, proteinuria and albuminuria may be treated, their progression slowed or their onset delayed or prevented. The term tissue ischaemia particularly comprises diabetic macroangiopathy, diabetic microangiopathy, impaired wound healing and diabetic ulcer. The terms micro- and macrovascular diseases and micro- and macrovascular complications are used interchangeably in this application.
According to another aspect of the invention, there is provided a method for preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 2 diabètes mellitus, impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, overweight, obesity, metabolic syndrome, gestational diabètes and diabètes related to cystic fibrosis in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
According to another aspect of the invention, there is provided a method for improving glycémie control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient,
-8The pharmaceutical composition according to this invention may also hâve valuable diseasemodifying properties with respect to diseases or conditions related to impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), insulin résistance and/or metabolic syndrome.
According to another aspect of the invention, there is provided a method for preventing, slowing, delaying or reversing progression from impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), insulin résistance and/or from metabolic syndrome to type 2 diabètes mellitus in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
As by the use of a pharmaceutical composition according to this invention, an improvement of the glycémie control in patients in need thereof is obtainable, also those conditions and/or diseases related to or caused by an increased blood glucose level may be treated.
By the administration of a pharmaceutical composition according to this invention and due to the activity of the SGLT2 inhibitor excessive blood glucose Ievels are not converted to insoluble storage forms, like fat, but excreted through the urine of the patient. In animal models using a SGLT2 inhibitor it can be seen that loss of fat accounts for the majority of the observed weight loss whereas no significant changes in body water or protein content are observed. Therefore, no or less gain in weight or even a réduction in body weight is the resuit.
According to another aspect of the invention, there is provided a method for reducing body weight and/or body fat or preventing or attenuating an increase in body weight and/or body fat or facilitating a réduction in body weight and/or body fat in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
By the administration of a combination or pharmaceutical composition according to the présent invention, an abnormal accumulation of ectopic fat, in particular of the liver, may be reduced or inhibited. Therefore, according to another aspect of the présent invention, there is provided a method for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat, in particular of the liver, in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient. Diseases or conditions which are attributed to an abnormal accumulation of liver fat are particularly selected from the group consisting of general fatty liver, non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis w
-9(NASH), hyperalimentation-induced fatty Iiver, diabetic fatty iiver, alcoholic-induced fatty li' or toxic fatty Iiver.
As a resuit thereof, another aspect of the invention provides a method for maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin résistance in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
According to another aspect of the invention, there is provided a method for preventing, slowing progression of, delaying, or treating new onset diabètes after transplantation (NODAT) and/or post-transplant metabolic syndrome (PTMS) in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
According to a further aspect of the invention, there is provided a method for preventing, delaying, or reducing NODAT and/or PTMS associated complications including micro- and macrovascular diseases and events, graft rejection, infection, and death in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
According to another aspect of the invention, there is provided a method for preventing, slowing progression of, delaying, or treating diabètes associated with cystic fibrosis in a patient In need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient
The pharmaceutical composition according to the invention is capable of facilitating the lowering of sérum total urate levels in the patient. Therefore according to another aspect of the invention, there is provided a method for treating hyperuricemia and hyperuricemiaassociated conditions, such as for example goût, hypertension and rénal failure, in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient.
The administration of a pharmaceutical composition increases the urine excrétion of glucose.
This increase in osmotic excrétion and water release and the lowering of urate levels are bénéficiai as a treatment or prévention for kidney stones. Therefore in a further aspect of the invention, there is provided a method for treating or preventing kidney stones in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient. <λ/ ί 6387
- ιοAccording to a further aspect of the invention, there is provided a method for treating hyponatremia, water rétention and water intoxication in a patient in need thereof characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient By the administration of the pharmaceutical composition according to this invention it may be possible to reverse the effects of hyponatremia, water rétention and water intoxication by acting on the kidney to reverse water rétention and electrolyte imbalances associated with these diseases and disorders.
According to another aspect of the invention there is provided the use of an SGLT2 inhibitor for the manufacture of a médicament for
- treating diabètes mellitus;
- treating diabètes mellitus, where treatment with insulin is required;
- treating type 1 diabètes mellitus;
- treating, preventing or reducing the risk of hypoglycemia;
- preventing, slowing progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus;
- preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 diabètes mellitus, type 2 diabètes mellitus, impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, overweight, obesity, metabolic syndrome and gestational diabètes; or
- improving glycémie control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c; or
- preventing, slowing, delaying or reversîng progression from impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), insulin résistance and/or from metabolic syndrome to type 2 diabètes mellitus; or
- preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, arteriosclerosis, myocardial infarction, stroke and peripheral arterial occlusive disease; or
- reducing body weight and/or body fat or preventing or attenuating an increase in body weight and/or body fat or facilitating a réduction in body weight and/or body fat; or
- preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat; or
- maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin résistance; ajv''’’' k
- preventing, slowing progression of, delaying, or treating new onset diabètes after transplantation (NODAT) and/or post-transplant metabolic syndrome (PTMS);
- preventing, delaying, or reducing NODAT and/or PTMS associated complications including micro- and macrovascular diseases and events, graft rejection, infection, and death;
- treating diabètes associated with cystic fibrosis
- treating hyperuricemia and hyperuricemia associated conditions;
- treating or prévention kidney stones;
- treating hyponatremia;
in a patient in need thereof characterized în that the SGLT2 inhibitor is administered, for example in combination or alternation, with an insulin.
According to another aspect of the invention, there is provided the use of an insulin for the manufacture of a médicament for
- treating diabètes mellitus;
- treating diabètes mellitus, where treatment with insulin is required;
- treating type 1 diabètes mellitus;
- treating, preventing or reducing the risk of hypoglycemia;
- preventing, slowing progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus;
- preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 diabètes mellitus, type 2 diabètes mellitus, impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), hyperglycemia, postprandial hyperglycemia, overweight, obesity and metabolic syndrome; or
- improving glycémie control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c; or
- preventing, slowing, delaying or reversing progression from impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), insulin résistance and/or from metabolic syndrome to type 2 diabètes mellitus; or
- preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, arteriosclerosis, myocardial infarction, stroke and peripheral arterial occlusive disease; or
- reducing body weight and/or body fat or preventing or attenuating an increase in body weight and/or body fat or facilitating a réduction in body weight and/or body fat; or
- preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of liver fat; or
- maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin résistance;
in a patient in need thereof characterized in that the insulin is administered, for example in combination or alternation, with an SGLT2 inhibitor.
According to another aspect of the invention, there is provided the use of a pharmaceutical composition according to the présent invention for the manufacture of a médicament for a therapeutic and préventive method as described hereinbefore and hereinafter.
Définitions
The term active ingrédient” of a pharmaceutical composition according to the présent invention means the SGLT2 inhibitor and/or the long acting insulin according to the présent invention.
The term body mass index or BMI of a human patient is defîned as the weight in kilograms divided by the square of the height in meters, such that BMI has units of kg/m2.
The term overweight is defîned as the condition wherein the individual has a BMI greater than or 25 kg/m2 and less than 30 kg/m2. The terms overweight and pre-obese are used interchangeably.
The term obesity is defîned as the condition wherein the individual has a BMI equal to or greater than 30 kg/m2. According to a WHO définition the term obesity may be categorized as follows; the term class I obesity is the condition wherein the BMI is equal to or greater than 30 kg/m2 but lower than 35 kg/m2; the term class II obesity is the condition wherein the BMI is equal to or greater than 35 kg/m2 but lower than 40 kg/m2; the term class III obesity is the condition wherein the BMI is equal to or greater than 40 kg/m2.
The term viscéral obesity is defîned as the condition wherein a waist-to-hip ratio of greater than or equal to 1.0 in men and 0.8 in women is measured. It defines the risk for insulin résistance and the development of pre-diabetes.
The term abdominal obesity is usually defîned as the condition wherein the waist circumference is > 40 inches or 102 cm in men, and is > 35 inches or 94 cm in women. With regard to a Japanese ethnicity or Japanese patients abdominal obesity may be defîned as waist circumference £ 85 cm in men and £ 90 cm in women (see e.g. investigating committee for the diagnosis of metabolic syndrome in Japan).
-13The term “euglycemia” is defined as the condition in which a subject has a fasting blood glucose concentration within the normal range, greater than 70 mg/dl_ (3.89 mmol/L) and less than 100 mg/dl_ (5.6 mmol/L). The word ‘‘fasting” has the usual meaning as a medical term.
The term “hyperglycemia” is defined as the condition in which a subject has a fasting blood glucose concentration above the normal range, greater than 100 mg/dL (5.6 mmol/L). The word “fasting has the usual meaning as a medical term.
The term “hypoglycemia” is defined as the condition in which a subject has a blood glucose concentration below the normal range, in particular below 70 mg/dL (3.89 mmol/L) or even below 60 mg/dl.
The term postprandial hyperglycemia is defined as the condition in which a subject has a 2 hour postprandial blood glucose or sérum glucose concentration greater than 200 mg/dL (11.1 mmol/L).
The term “impaired fasting blood glucose” or IFG is defined as the condition in which a subject has a fasting blood glucose concentration or fasting sérum glucose concentration in a range from 100 to 125 mg/dl (i.e. from 5.6 to 6.9 mmol/l), in particular greater than 110 mg/dl_ and less than 126 mg/dl (7.00 mmol/L). A subject with normal fasting glucose has a fasting glucose concentration smaller than 100 mg/dl, i.e. smaller than 5.6 mmol/l.
The term “impaired glucose tolérance” or IGT is defined as the condition in which a subject has a 2 hour postprandial blood glucose or sérum glucose concentration greater than 140 mg/dl (7.8 mmol/L) and less than 200 mg/dl_ (11.11 mmol/L). The abnormal glucose tolérance, i.e. the 2 hour postprandial blood glucose or sérum glucose concentration can be measured as the blood sugar level in mg of glucose per dL of plasma 2 hours after taking 75 g of glucose after a fast. A subject with normal glucose tolérance has a 2 hour postprandial blood glucose or sérum glucose concentration smaller than 140 mg/dl (7.8 mmol/L).
The term “hyperinsulinemia” is defined as the condition in which a subject with insulin résistance, with or without euglycemia, has fasting or postprandial sérum or plasma insulin concentration elevated above that of normal, lean individuals without insulin résistance, having a waist-to-hip ratio <1.0 (for men) or < 0.8 (for women).
-14The terms insulin-sensitizing, ''insulin resistance-improving or insulin resistance-lowering” are synonymous and used interchangeably.
The term “insulin résistance” is defined as a state in which circulating insulin levels in excess of the normal response to a glucose load are required to maintain the euglycemic state (Ford ES, et al. JAMA. (2002) 287:356-9). A method of determining insulin résistance is the euglycaemic-hyperinsulinaemic clamp test The ratio of insulin to glucose is determined within the scope of a combined insulin-glucose infusion technique. There is found to be insulin résistance if the glucose absorption is below the 25th percentile of the background population investigated (WHO définition). Rather less laborious than the clamp test are so called minimal models in which, during an intravenous glucose tolérance test, the insulin and glucose concentrations In the blood are measured at fixed time intervals and from these the insulin résistance is calculated. With this method, it is not possible to distinguish between hepatic and peripheral insulin résistance.
Furthermore, insulin résistance, the response of a patient with insulin résistance to therapy, insulin sensitivity and hyperinsulinemia may be quantified by assessîng the “homeostasis model assessment to insulin résistance (HOMA-IR)” score, a reliable indicator of insulin résistance (Katsuki A, et al. Diabètes Care 2001; 24: 362-5). Further reference is made to methods for the détermination of the HOMA-index for insulin sensitivity (Matthews et al., Diabetologia 1985, 28:412-19), ofthe ratio of intact proinsulin to insulin (Forst et al., Diabètes 2003, 52(Suppl.1): A459) and to an euglycemic clamp study. In addition, plasma adiponectin levels can be monitored as a potential surrogate of insulin sensitivity. The estimate of insulin résistance by the homeostasis assessment model (HOMA)-IR score is calculated with the formula (Galvin P, étal. Diabet Med 1992;9:921-8):
HOMA-IR = [fasting sérum insulin (pU/mL)] x [fasting plasma glucose(mmol/L)/22.5]
As a rule, other parameters are used in everyday clinical practice to assess insulin résistance. Preferably, the patient’s triglycéride concentration is used, for example, as increased triglycéride levels correlate significantly with the presence of insulin résistance.
Patients with a prédisposition for the development of IGT or IFG or type 2 diabètes are those having euglycemia with hyperinsulinemia and are by définition, insulin résistant. A typical patient with insulin résistance is usually overweight or obese, but this is not always the case.
If insulin résistance can be detected, this is a particularly strong indication of the presence of pre-diabetes. Thus, it may be that in order to maintain glucose homoeostasis a person hâve n/
-15e.g. 2-3 times as high endogenous insulin production as a healthy person, without this resulting in any clinical symptoms.
The methods to investigate the function of pancreatic beta-cells are similar to the above methods with regard to insulin sensitivity, hyperinsulinemia or insulin résistance: An improvement of beta-cell function can be measured for example by determining a HOMAindex for beta-cell function (Matthews et al., Diabetologia 1985, 28:412-19), the ratio of intact proinsulin to insulin (Forst et al., Diabètes 2003, 52(Suppl. 1): A459), the insulin/Cpeptide sécrétion after an oral glucose tolérance test or a meal tolérance test, or by employing a hyperglycémie clamp study and/or minimal modeling after a frequently sampled intravenous glucose tolérance test (Stumvoll et al., Eur J Clin Invest 2001, 31: 380-81).
The term “pre-diabetes” is the condition wherein an individual is pre-disposed to the development of type 2 diabètes. Pre-diabetes extends the définition of impaired glucose tolérance to include individuals with a fasting blood glucose within the high normal range à 100 mg/dL (J. B. Meigs, et al. Diabètes 2003; 52:1475-1484) and fasting hyperinsulinemia (elevated plasma insulin concentration). The scientific and medical basis for identifying prediabetes as a serious health threat is laid out in a Position Statement entitled The Prévention or Delay of Type 2 Diabètes issued jointly by the American Diabètes Association and the National Institute of Diabètes and Digestive and Kidney Diseases (Diabètes Care 2002; 25:742-749).
Individuals likely to hâve insulin résistance are those who hâve two or more of the following attributes: 1) overweight or obese, 2) high blood pressure, 3) hyperlipidemia, 4) one or more 13t degree relative with a diagnosis of IGT or IFG or type 2 diabètes. Insulin résistance can be confirmed in these individuals by calculating the HOMA-IR score. For the purpose of this invention, insulin résistance is defined as the clinical condition in which an individual has a HOMA-IR score > 4.0 or a HOMA-IR score above the upper limit of normal as defined for the laboratory performing the glucose and insulin assays.
The term “type 1 diabètes” is defined as the condition in which a subject has, in the presence of autoimmunity towards the pancreatic beta-cell or insulin, a fasting blood glucose or sérum glucose concentration greater than 125 mg/dL (6.94 mmol/L). If a glucose tolérance test is carried out, the blood sugar level of a diabetic will be in excess of 200 mg of glucose per dL (11.1 mmol/l) of plasma 2 hours after 75 g of glucose hâve been taken on an empty stomach, in the presence of autoimmunity towards the pancreatic beta cell or insulin. In a glucose tolérance test 75 g of glucose are administered orally to the patient being tested after 10-12 hours of fasting and the blood sugar level is recorded immediately before taking
-16the glucose and 1 and 2 hours after taking it. The presence of autoimmunity towards the pancreatic beta-cell may be observed by détection of circulating islet cell autoantibodies [“type 1A diabètes mellitus”], i.e., at least one of: GAD65 [glutamic acid decarboxylase-65], ICA [islet-cell cytoplasm], IA-2 [intracytoplasmatic domain of the tyrosine phosphatase-like protein IA-2], ZnT8 [zinc-transporter-8] or anti-insulin; or other signs of autoimmunity without the presence of typical circulating autoantibodies [type 1B diabètes], i.e. as detected through pancreatic biopsy or imaging). Typically a genetic prédisposition is présent (e.g. HLA, INS VNTR and PTPN22), but this is not always the case.
The term “type 2 diabètes is defined as the condition in which a subject has a fasting blood glucose or sérum glucose concentration greater than 125 mg/dL (6.94 mmol/L). The measurement of blood glucose values is a standard procedure in routine medical analysis. If a glucose tolérance test is carried out, the blood sugar level of a diabetic will be in excess of 200 mg of glucose per dL (11.1 mmol/l) of plasma 2 hours after 75 g of glucose hâve been taken on an empty stomach. In a glucose tolérance test 75 g of glucose are administered orally to the patient being tested after 10-12 hours of fasting and the blood sugar level is recorded immediately before taking the glucose and 1 and 2 hours after taking it In a healthy subject, the blood sugar level before taking the glucose will be between 60 and 110 mg per dL of plasma, less than 200 mg perdL 1 hour after taking the glucose and less than 140 mg per dL after 2 hours. If after 2 hours the value is between 140 and 200 mg, this is regarded as abnormal glucose tolérance.
The term late stage type 2 diabètes mellitus includes patients with a secondary drug failure, indication for insulin therapy and progression to micro- and macrovascular complications e.g. diabetic nephropathy, or coronary heart disease (CHD).
The term HbA1c refers to the product of a non-enzymatic glycation of the haemoglobin B chain. Its détermination is well known to one skilled in the art. In monitoring the treatment of diabètes mellitus the HbA1c value is of exceptional importance. As its production dépends essentially on the blood sugar level and the life of the érythrocytes, the HbA1c in the sense of a blood sugar memory reflects the average blood sugar levels of the preceding 4-6 weeks. Diabetic patients whose HbA1c value is consistently well adjusted by intensive diabètes treatment (i.e. < 6.5 % of the total haemoglobin in the sample), are significantly better protected against diabetic microangiopathy. For example, metformin on its own achieves an average improvement in the HbA1 c value in the diabetic of the order of 1.0 - 1.5 %. This réduction ofthe HbA1C value is not sufficient in ail diabetics to achieve the desired target range of < 6.5 % and preferably < 6 % HbA1c. xy/
-17The term insufficient glycémie control or inadéquate glycémie control in the scope of the présent invention means a condition wherein patients show HbA1c values above 6.5 %, in particular above 7.0 %, even more preferably above 7.5 %, especially above 8 %.
The “metabolic syndrome”, also called “syndrome X (when used in the context of a metabolic disorder), also called the “dysmetabolic syndrome” is a syndrome complex with the cardinal feature being insulin résistance (Laaksonen DE, et al. Am J Epidemiol 2002;156:1070-7). According to the ATP lll/NCEP guidelines (Executive Summary of the Third Report of the National Cholestérol Education Program (NCEP) Expert Panel on Détection, Evaluation, and Treatment of High Blood Cholestérol in Adults (Adult Treatment Panel III) JAMA: Journal ofthe American Medical Association (2001) 285:2486-2497), diagnosis of the metabolic syndrome is made when three or more of the following risk factors are présent:
1. Abdominal obesity, defined as waist circumference > 40 inches or 102 cm in men, and > 35 inches or 94 cm in women; or with regard to a Japanese ethnicity or Japanese patients defined as waist circumference 2:85 cm in men and a 90 cm in women;
2. Triglycérides: a 150 mg/dL
3. HDL-cholesterol < 40 mg/dL in men
4. Blood pressure s 130/85 mm Hg (SBP z 130 or DBP £ 85)
5. Fasting blood glucose a 100 mg/dL
The NCEP définitions have been validated (Laaksonen DE, et al. Am J Epidemiol. (2002) 156:1070-7). Triglycérides and HDL cholestérol in the blood can also be determined by standard methods in medical analysis and are described for example in Thomas L (Editor): Labor und Diagnose, TH-Books Verlagsgesellschaft mbH, Frankfurt/Main, 2000.
According to a commonly used définition, hypertension is diagnosed if the systolic blood pressure (SBP) exceeds a value of 140 mm Hg and diastolic blood pressure (DBP) exceeds a value of 90 mm Hg. If a patient is suffering from manifest diabètes it is currently recommended that the systolic blood pressure be reduced to a level below 130 mm Hg and the diastolic blood pressure be lowered to below 80 mm Hg.
The définitions of NODAT (new onset diabètes after transplantation) and PTMS (posttransplant metabolic syndrome) follow closely that of the American Diabètes Association diagnostic criteria for type 2 diabètes, and that ofthe International Diabètes Fédération (IDF) and the American Heart Association/National Heart, Lung, and Blood Institute, for the metabolic syndrome. NODAT and/or PTMS are associated with an increased risk of micro- v.
-18and macrovascular disease and events, graft rejection, infection, and death. A number of predictors hâve been identified as potential risk factors related to NODAT and/or PTMS including a higher âge at transplant, male gender, the pre-transplant body mass index, pretransplant diabètes, and immunosuppression.
The term gestational diabètes (diabètes of pregnancy) dénotés a form of the diabètes which develops during pregnancy and usually ceases again immediately after the birth. Gestational diabètes is diagnosed by a screening test which is carried out between the 24th and 28th weeks of pregnancy. It is usually a simple test in which the blood sugar level is measured one hour after the administration of 50 g of glucose solution. If this 1 h level is above 140 mg/dl, gestational diabètes is suspected. Final confirmation may be obtained by a standard glucose tolérance test, for example with 75 g of glucose.
The term hyperuricemia dénotés a condition of high sérum total urate levels. ln human blood, uric acid concentrations between 3.6 mg/dL (ca. 214 pmol/L) and 8.3 mg/dl_ (ca. 494 pmol/L) are considered normal by the American Medical Association. High sérum total urate levels, or hyperuricemia, are often associated with several maladies. For example, high sérum total urate levels can lead to a type of arthritis in the joints kown as goût. Goût is a condition created by a build up of monosodium urate or uric acid crystals on the articular cartilage of joints, tendons and surrounding tissues due to elevated concentrations of total urate levels in the blood stream. The build up of urate or uric acid on these tissues provokes an inflammatory reaction of these tissues. Saturation levels of uric acid in urine may resuit in kidney stone formation when the uric acid or urate crystallizes in the kidney. Additionally, high sérum total urate levels are often associated with the so-called metabolic syndrome, including cardiovascular disease and hypertension.
The term hyponatremia dénotés a condition of a positive balance of water with or without a déficit of sodium, which is recognized when the plasma sodium falls below the level of 135 mml/L. Hyponatremia is a condition which can occur in isolation in individuals that overconsume water; however, more often hyponatremia is a complication of médication or other underlying medical condition that leas to a diminished excrétion of water. Hyponatremia may lead to water intoxication, which occurs when the normal tonicity of extracellular fluid falls below the safe limit, due to rétention of excess water. Water intoxication is a potentially fatal disturbance in brain function. Typical symptoms of water intoxication include nausea, vomiting, headache and malaise.
The term SGLT2 inhibitor in the scope of the présent invention relates to a compound, in particular to a glucopyranosyl-derivative, i.e. compound having a glucopyranosyl-moiety,
-19which shows an inhibitory effect on the sodium-glucose transporter 2 (SGLT2), in particular the human SGLT2. The inhibitory effect on hSGLT2 measured as IC50 is prerably below 1000 nM, even more preferably below 100 nM, most preferably below 50 nM. IC50 values of SGLT2 inhibitors are usually above 0.01 nM, or even equal to or above 0.1 nM. The inhibitory effect on hSGLT2 can be determined by methods known in the literature, in particular as described in the application WO 2005/092877 or WO 2007/093610 (pages 23/24), which are incorporated herein by reference in its entirety. The term SGLT2 inhibitor also comprises any pharmaceutically acceptable salts thereof, hydrates and solvatés thereof, including the respective crystalline forms.
The term insulin in the scope of the présent invention relates to insulin and insulin analogs being used in the therapy of patients, in particular humans, which includes normal insulin, human insulin, insulin dérivatives, zinc insulins and insulin analogues, including formulations thereof with modified release profiles, in particular as used in the therapy of humans. The term insulin in the scope of the présent invention covers the following types of insulins:
- rapid-acting insulins,
- short-acting insulins,
- intermediate-acting insulins,
- long-acting insulins, and mixtures thereof, for example mixtures of short- or rapid-acting insulins with long-acting insulins. The term insulin in the scope of the présent invention covers insulins which are administered to the patient via injection, via infusion, including pumps, via inhalation, via oral, via transdermal or other routes of administration.
The terms treatment and treating comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form. Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the spécifie indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease. Thus the compositions and methods of the présent invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.
The terms prophylactically treating, preventivally treating and preventing are used interchangeably and comprise a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
Brief Description of the Figures %aA
-20The Figure 1 shows the blood glucose line in rats after administration of a SGLT2 inhibitor, insulin glargine and a combination thereof.
The Figure 2 shows the blood glucose line in rats after administration of a low-dose insulin glargine, a high dose insulin glargine and a combination of a SGLT2 inhibitor with a low dose of insulin glargine.
The Figure 3 shows the blood glucose line in rats after administration of insulin glargine and a co-administration of a SGLT2 inhibitor after 120 minutes.
The Figure 4 shows the effect on body fat portion after implantation of insulîn-releasing sticks and after administration of a SGLT2 inhibitor alone and in addition to the implants.
Detailed Description
The aspects according to the présent invention, in particular the pharmaceutical compositions, methods and uses, refer to SGLT2 inhibitors and insulins. In the methods and uses according to this invention a third antidiabetic agent may optionally be administered, i.e. the SGLT2 inhibitor and the insulin are administered in combination without a third antidiabetic agent or with a third antidiabetic agent.
Preferably the SGLT2 inhibitor is selected from the group G1 consisting of dapagliflozin, canagliflozin, atigliflozin, ipragliflozin, tofogliflozin, remogliflozin, sergliflozin and glucopyranosyl-substituted benzene dérivatives of the formula (I)
wherein R1 dénotés Cl, methyl or cyano; R2 dénotés H, methyl, methoxy or hydroxy and R3 dénotés ethyl, cyclopropyl, ethynyl, ethoxy, (R)-tetrahydrofuran-3-yloxy or (S)tetrahydrofuran-3-yloxy; or a prodrug of one of the beforementioned SGLT2 inhibitors.
Compounds of the formula (I) and methods of their synthesis are described for example in the following patent applications: WO 2005/092877, WO 2006/117360, WO 2006/117359, WO 2006/120208, WO 2006/064033, WO 2007/031548, WO 2007/093610, WO 2008/020011, WO 2008/055870.
In the above glucopyranosyl-substituted benzene dérivatives of the formula (I) the following définitions of the substituents are preferred. ά/
-21 Preferably R1 dénotés chloro or cyano; in particular chloro.
Preferably Rz dénotés H.
Preferably R3 dénotés ethyl, cyclopropyl, ethynyl, (R)-tetrahydrofuran-3-yloxy or (SJtetrahydrofuran-3-yloxy. Even more preferably R3 dénotés cyclopropyl, ethynyl, (R)5 tetrahydrofuran-3-yloxy or (S)-tetrahydrofuran-3-yloxy. Most preferably R3 dénotés ethynyl, (R)-tetrahydrofuran-3-yloxy or (S)-tetrahydrofuran-3-yloxy.
Preferred glucopyranosyl-substituted benzene dérivatives of the formula (I) are selected from the group of compounds (1.1) to (1.11):
(M) | ho HO'OH OH 6-(4-ethylbenzyl)-4-(p | jT -D-glucopyranos-1-yl)-2-methoxy-benzonitrile, |
I °ΤΊι | Y* Λ | |
r | ||
(I.2) | ||
HO' ' γ^0Η | ||
OH | ||
2-(4-ethylbenzyl)-4-(P-D-glucopyranos-1-yl)-5-methoxy-benzonitrile, | ||
I | ||
(I.3) | ho γ | |
HO’” ηρ OH | ||
OH | ||
1-cyano-2-(4-ethylbenzyl)-4-(p-D-glucopyranos-1-yl)-5-methyl-benzene, | ||
ΗΟγΤτ | Y* | |
/X/OvAJ | ||
(I.4) | ho | |
HO' OH | ||
OH | ||
2-(4-ethylbenzyl)-4-(p-D-glucopyranos-1-yl)-5-hydroxy-benzonitrile, |
(I.5) | Ηθ' γχ>'0Η ΟΗ 2-(4-ethyl-benzyl)-4-(P-D-glucopyranos-1-yl)-benzonitrile, |
(I.6) | Η ο ''γ Η0’’’^γ ΟΗ ΟΗ 2-(4-cyclopropyl-benzyl)-4-(p-D-glucopyranos-1-yl)-benzonitrilel |
(Ι·7) | ΗΟ”'ΟΗ ΟΗ 1-chloro-4-(p-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, |
(I.8) | ^°JuCu ηο'“ Όη ΟΗ 1-chloro-4-(p-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)benzylj-benzene, |
(I.9) | zyO,, . JUVU c° HO' ηρ OH OH 1-chloro-4-(P-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)benzyl]-benzene, |
(MO) | ho I Ho'',ksy OH 1-methyl-2-[4-( yl)-benzene, | 'OH (R)-tetrah | Xr°x> ydrofuran-3-yloxy)-benzyl]-4-(p-D-glucopyranos-1- |
xro | |||
HO N | |||
(MD | ho' γ | ’OH | |
OH | |||
1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-4-(P-D-glucopyranos-1- | |||
yl)-benzene. |
According an embodiment of the présent invention the SGLT2 inhibitor is selected from the group G1a consisting of compounds of the beforementioned formula (I). Even more preferably the group G1a consists of glucopyranosyl-substituted benzene dérivatives of the formula (I) which are selected from the compounds (I.6), (I.7), (I.8), (I.9) and (1.11). An preferred example of a SGLT2 inhibitor according to the group G1a is the compound (I.9).
According to another embodiment of the présent invention the SGLT2 inhibitor is selected from the group consisting of dapagliflozin, canagliflozin, atigliflozin, ipragliflozin and tofogliflozin.
According to this invention, it is to be understood that the définitions of the above listed SGLT2 inhibitors, including the glucopyranosyl-substituted benzene dérivatives of the formula (I), also comprise their hydrates, solvatés and polymorphie forms thereof, and prodrugs thereof. With regard to the preferred compound (I.7) an advantageous crystalline form is described in the international patent application WO 2007/028814 which hereby is încorporated herein in its entirety. With regard to the preferred compound (I.8), an advantageous crystalline form is described in the international patent application WO 2006/117360 which hereby is încorporated herein in its entirety. With regard to the preferred compound (I.9) an advantageous crystalline form is described in the international patent application WO 2006/117359 which hereby is încorporated herein in its entirety. With regard to the preferred compound (1.11) an advantageous crystalline form is described in the international patent application WO 2008/049923 which hereby is încorporated herein in its •xK'
-24entirety. These crystalline forms possess good solubility properties which enable a good bioavailability of the SGLT2 inhibitor. Furthermore, the crystalline forms are physicochemically stable and thus provide a good shelf-life stability of the pharmaceutical composition.
The term dapagliflozin as employed herein refers to dapagliflozin, including hydrates and solvatés thereof, and crystalline forms thereof. The compound and methods of its synthesis are described in WO 03/099836 for example. Preferred hydrates, solvatés and crystalline forms are described in the patent applications WO 2008/116179 and WO 2008/002824 for example.
The term canagliflozin as employed herein refers to canagliflozin, including hydrates and solvatés thereof, and crystalline forms thereof and has the following structure:
The compound and methods of its synthesis are described in WO 2005/012326 and WO 2009/035969 for example. Preferred hydrates, solvatés and crystalline forms are described in the patent applications WO 2008/069327 for example.
The term atigliflozin as employed herein refers to atigliflozin, including hydrates and solvatés thereof, and crystalline forms thereof and has the following structure:
The compound and methods of its synthesis are described in WO 2004/007517 for example.
The term ipragliflozin as employed herein refers to ipragliflozin, including hydrates and solvatés thereof, and crystalline forms thereof and has the following structure:
-25HO
OH
The compound and methods of its synthesîs are described in WO 2004/080990, WO 2005/012326 and WO 2007/114475 for example.
The term tofogliflozin as employed herein refers to tofogliflozin, including hydrates and solvatés thereof, and crystalline forms thereof and has the following structure:
HO
HO
ch3
The compound and methods of Its synthesîs are described in WO 2007/140191 and WO 2008/013280 for example.
The term remogliflozîn as employed herein refers to remogliflozin and prodrugs of remogliflozin, in particular remogliflozin etabonate, including hydrates and solvatés thereof, and crystalline forms thereof. Methods of its synthesîs are described in the patent applications EP 1213296 and EP 1354888 for example.
The term sergliflozin as employed herein refers to sergliflozin and prodrugs of sergliflozin, in particular sergliflozin etabonate, including hydrates and solvatés thereof, and crystalline forms thereof. Methods for its manufacture are described in the patent applications EP 1344780 and EP 1489089 for example.
For avoidance of any doubt, the disclosure of each of the foregoing documents cited above in connection with the specified SGLT2 inhibitors is specifically incorporated herein by reference in its entirety.
The aspects according to the présent invention, in particular the pharmaceutical compositions, methods and uses, refer to an insulin, which includes normal insulin, human insulin, insulin dérivatives, zinc insulins and insulin analogues, including formulations thereof w
-26with modified release profiles, in particular as used in the therapy of humans. The insulin may be selected from the group consisting of:
- rapid-acting insulins,
- short-acting insulins,
- intermediate-acting insulins,
- long-acting insulins, and mixtures thereof.
Mixtures of insulins may comprise mixtures of short- or rapid-acting insulins with long-acting insulins. For example such mixtures are marketed as Actraphane/Mixtard or Novomix.
The term insulin in the scope of the présent invention covers insulins as described hereînbefore and hereinafter which are administered to the patient via injection, preferably subcutaneous injection, via infusion, including pumps, via inhalation or other routes of administration. Insulins to be administered via inhalation are for example Exubera (Pfizer), AIR (Lilly) and AER (Novo Nordisk).
Rapid-acting insulins usually start lowering the blood glucose within about 5 to 15 minutes and are effective for about 3 to 4 hours. Examples of rapid-acting insulins are insulin aspart, insulin lispro and insulin glulisine. Insulin Lispro is marketed under the trade name Humalog and Liprolog. Insulin Aspart is marketed under the trade names NovoLog and NovoRapid. Insulin glulisine is marketed under the trade name Apidra.
Short-acting insulins usually start lowering the blood glucose within about 30 minutes and are effective about 5 to 8 hours. An example is regular insulin or human insulin.
Intermediate-acting insulins usually start lowering the blood glucose within about 1 to 3 hours and are effective for about 16 to 24 hours. An example is NPH insulin, also known as Humulin N, Novolin N, Novolin NPH and isophane insulin. Another example are lente insulins, such as Semilente or Monotard.
Long-acting insulins usually start lowering the blood glucose within 1 to 6 hours and are effective for up to about 24 hours or even up to or beyond 32 hours. Long-acting insulin usually provides a continuous level of insulin activity (for up to 24-36 hours) and usually opérâtes at a maximum strength (with fiat action profile) after about 8-12 hours, sometimes longer. Long-acting insulin is usually administered in the morning or before bed. Examples of long-acting insulin may include, but are not limited to, insulin glargine, insulin detemir or insulin degludec, which are insulin analogues, and ultralente insulin, which is regular human u/
-27insulin formulated for slow absorption. Long-acting insulin is suited to provide for basal, as opposed to prandial, insulin requirements (e.g. to control hyperglycemia). Long-acting insulin may be typically administered ranging from twice or once daily, over thrice weekly up to once weekly (ultra long-acting insulin). Insulin glargine is marketed under the trade name Lantus for example. Insulin detemir is marketed under the tradename Levemir for example.
In one embodiment, the long-acting insulin of this invention refers to any insulin known in the art which is used for a basal insulin therapy and which hâve a basal release profile. A basal release profile refers to the kinetic, amount and rate of release of the insulin from the formulation into a patient's systemic circulation. In a graph of the patient's mean plasma insulin levels over time, a basal release profile typically has a minimal peak (often referred to as a peakless profile or “fiat profile) and slowly and continuously releases insulin for a prolonged period of time.
In a further embodiment, the long-acting insulin is an acylated dérivative of human insulin. Acylated insulin dérivatives may be such wherein a lipophilie group is attached to the lysine residue in position B29. A commercial product is Levemir® comprising LysBZ9(NEtetradecanoyl) des(B30) human insulin (insulin detemir). Another example is Ν£02θ-(Να-(ωcarboxypentadecanoyl)-L-Y-glutamyl) des(B30) human insulin (insulin degludec).
In a further embodiment, the long-acting insulin is such comprising positively charged amino acids such as Arg attached to the C-terminal end of the B-chain. A commercial product is Lantus® (insulin glargine) comprising Gly*21, Arg031, Arg032 human insulin.
According to one embodiment of the invention the insulin is selected from the group consisting of long acting insulins.
According to another embodiment the insulin is selected from the group G2 consisting of the long acting insulins (L1 ) to (L7) as described hereinafter:
(L1): Insulin glargine
Insulin glargine (marketed as LANTUS® by Sanofî-Aventis) is approved and marketed for subcutaneous administration once a day. Insulin glargine provides relatively constant glucose lowering activity over a 24-hour period and may be administered any time during the day provided it is administered at the same time every day.
(L2): Insulin detemir
-28Insulin detemir (marketed as LEVEMIR® by Novo Nordisk) is approved and marketed for subcutaneous administration either twice a day or once a day, preferably with the evening meal or at bedtime.
(L3): Insulin degludec
Insulin degludec (NN1250) is a neutral, soluble ultra-long acting insulin with a duration of action more than 24 hours. Degludec has a very fiat, predictable and smooth action profile. It is intended for subcutaneous administration once daily or less (e.g. three times a week).
(L4): Insulin lispro PEGylated
Insulin lispro PEGylated with high molecular weight poly(ethylene glycol) dérivatives especially as disclosed in WO 2009/152128 (the disclosure of which îs incorporated herein), such as e.g, the PEGylated insulin lispro compound of the formula P-[(A)-(B)], or a pharmaceutically acceptable sait thereof, wherein A is the A-chain of insulin lispro, B is the B-chain of insulin lispro, and P is a PEG having a molecular weight in the range from about
17,5 kDa to about 40 kDa, and wherein A and B are properly cross-Iinked and P is attached via a urethane covalent bond to the epsilon-amino group of the lysine at position 28 of B.
(L5): Amidated insulin glargine
Amidated insulin glargine especially in the form of Gly*21, Arg631, ArgB32-NH2 human insulin (insulin glargine amide, i.e. the C-terminus of the B-chain of insulin glargine is amidated) as disclosed in WO 2008/006496 or WO 2008/006496 (the disclosures of which are incorporated herein).
(L6):
LysB29(NE-lithocholyl-Y-Glu) des(B30) human insulin or NtB29-œ-carboxypentadecanoyl-yamino-butanoyl des(B30) human insulin.
(L7):
Amidated insulin analogs as disclosed in WO 2009/087082 (the disclosure of which is incorporated herein), especially one selected from claim 14, or in WO 2009/087081 (the disclosure of which is incorporated herein), especially one selected from claim 16.
Preferred members of the group G2 are L1, L2 and L3, in particular insulin glargine.
Long-acting insulins analogues are typically given as basic anti-diabetic therapy to type 1 diabètes, type 2 diabètes or latent autoimmune diabètes with onset in adults (LADA) patients to control the blood sugar when no food intake occurs. As mentioned above, this type of
-29insulin provides a continuous level of insulin activity for up to 36 hours. Long-acting insulin opérâtes at maximum strength after about 8-12 hours. Because of their advantages, it is thought that treatment with these insulin analogues can lead to a bénéficiai effect, for example less hypoglycaemia, less weight gain or a better metabolic control possibly resulting in less late diabetic complications such as problems with eyes, kidneys or feet and myocardial infarction, stroke or death.
According to the invention, there are provided methods for treating a patient with regard to diseases and conditions as described hereinbefore and hereinafter characterized in that an SGLT2 inhibitor and an insulin are administered, for example in combination or alternation, to the patient. Said diseases and conditions comprise diabètes mellitus, type 1 diabètes mellitus, type 2 diabètes mellitus, diseases which require treatment with insulin, conditions which require treatment with insulin, inter alia. According to one embodiment of the invention the insulin is part of a basal insulin therapy.
The term basal insulin therapy relates to a therapy in which one or more insulins are administered to a patient such that in a graph of the patient's mean plasma insulin leveis over time, a basal release profile typically has a minimal peak (often referred to as a peakless profile or “fiat profile’1) and slowly and continuously releases insulin for a prolonged period of time. According to one embodiment the basal insulin therapy includes the administration of a long-acting insulins to a patient. According to another embodiment the basal insulin therapy includes the administration of an insulin, in particular a rapid-acting or short-acting insulin, including human insulin, to a patient via infusion, for example via a pump in order to achieve the desired patient’s mean plasma insulin level for a prolonged period of time, for example over 12 or 24 hours or longer.
Therefore according to one embodiment of the invention there is provided a method for treating a disease or condition selected from the group consisting of diabètes mellitus, type 1 diabètes mellitus, type 2 diabètes mellitus and a disease or condition which requires treatment with insulin in a patient characterized in that the patient receives a basal insulin therapy and in addition a SGLT2 inhibitor is administered to the patient
According to one aspect of this embodiment the patient receives a basal insulin therapy wherein a long-acting insulin is administered to the patient. For example the long-acting insulin îs administered via injection, for example subcutaneous injection. Preferably the
SGLT2 inhibitor is administered orally. According to this aspect the long-acting insulin and the SGLT2 inhibitor are administered in combination or alternation, i.e. at the same time or at different times. For example the long-acting insulin is administered to the patient once or
-30twice, preferably once daily. For example the SGLT2 inhibitor is administered to the patient once or twice, preferably once daily.
According to another aspect of this embodiment the patient receives a basal insulin therapy wherein an insulin is administered to the patient via infusion, for example via a pump. According to this aspect the insulin may be a rapid-acting or short-acting insulin, for example a human insulin. Preferably the SGLT2 inhibitor is administered orally. According to this aspect the insulin and the SGLT2 inhibitor are administered in combination or alternation, i.e. at the same time or at different times. For example the insulin is administered to the patient several times daily via pump infusion wherein the time and dose are chosen in order to achieve a certain range of plasma insulin level. For example the SGLT2 inhibitor is administered to the patient once or twice, preferably once daily.
According to another embodiment of the présent invention the pharmaceutical composition, the methods and uses according to the invention additionally comprise a further antidiabetic agent.
A further antidiabetic agent is selected from the group G3 consisting of biguanides, thiazolidindiones, sulfonylureas, gllnides, inhibitors of alpha-glucosidase, GLP-1 analogues, DPP-4 inhibitors and amylin analogs, including pharmaceutically acceptable salts of the beforementioned agents. în the following preferred embodiments regarding the third antidiabetic agent are described.
The group G3 comprises biguanides. Examples of biguanides are metformin, phenformin and buformin. A preferred biguanide is metformin.
The term metformin as employed herein refers to metformin or a pharmaceutically acceptable sait thereof such as the hydrochloride sait, the metformin (2:1) fumarate sait, and the metformin (2:1) succinate sait, the hydrobromide sait, the p-chlorophenoxy acetate or the embonate, and other known metformin salts of mono and dibasic carboxylic acids. It is preferred that the metformin employed herein is the metformin hydrochloride sait.
The group G3 comprises thiazolidindiones. Examples of thiazolidindiones (TZD) are pioglitazone and rosiglitazone.
The term pioglitazone as employed herein refers to pioglitazone, including its enantiomers, mixtures thereof and its racemate, or a pharmaceutically acceptable sait thereof such as the hydrochloride sait.
-31 The term rosiglitazone as employed herein refers to rosiglitazone, including its enantiomers, mixtures thereof and its racemate, or a pharmaceutically acceptable sait thereof such as the maleate sait.
The group G3 comprises sulfonylureas. Examples of sulfonylureas are glibenclamide, tolbutamide, glimepiride, glipizide, gliquidone, glibornuride, glyburide, glisoxepide and gliclazide. Preferred sulfonylureas are tolbutamide, gliquidone, glibenclamide, glipizide and glimepiride, in particular glibenclamide, glipizide and glimepiride.
Each term of the group glibenclamide, glimepiride, gliquidone, glibornuride, gliclazide, glisoxepide, tolbutamide and glipizide as employed herein refers to the respective active drug or a pharmaceutically acceptable sait thereof.
The group G3 comprises glinides. Examples of glinides are nateglinide, repaglinide and mitiglinide.
The term nateglinide as employed herein refers to nateglinide, including its enantiomers, mixtures thereof and its racemate, or a pharmaceutically acceptable salts and esters thereof.
The term repaglinide as employed herein refers to repaglinide, including its enantiomers, mixtures thereof and its racemate, or a pharmaceutically acceptable salts and esters thereof.
The group G3 comprises inhibitors of alpha-glucosidase. Examples of inhibitors of alphaglucosidase are acarbose, voglibose and miglitol.
Each term of the group acarbose, voglibose and miglitol as employed herein refers to the respective active drug or a pharmaceutically acceptable sait thereof.
The group G3 comprises inhibitors of GLP-1 analogues. Examples of GLP-1 analogues are exenatide and liraglutide.
Each term of the group exenatide and liraglutide as employed herein refers to the respective active drug or a pharmaceutically acceptable sait thereof.
The group G3 comprises inhibitors of DPP-4 inhibitors. Examples of DPP-4 inhibitors are linagliptin, sitagliptin, vildagliptin, saxagliptin, denagliptin, alogliptin, carmegliptin, melogliptin,
-32dutogliptin, including pharmaceutically acceptable salts thereof, hydrates and solvatés thereof.
The group G3 comprises amylin analogs. An example of an amylin analog is pramlintide, including pharmaceutically acceptable salts thereof, hydrates and solvatés thereof. For example pramlintide acetate is marketed under the tradename Symlin.
According to an embodiment the pharmaceutical compositions, methods and uses according to the présent invention reiate to a combination of a SGLT2 inhibitor and an insulin which is 10 preferably selected from the group of sub-embodiments E1 to E36 according to the entries in the Table 1.
Table 1
Embodiment | SGLT2 Inhibitor | Insulin |
E1 | selected from the group G1 | insulin |
E2 | selected from the group G1 | rapid-acting or short-acting insulin |
E3 | selected from the group G1 | human insulin |
E4 | selected from the group G1 | intermediate-acting or longacting insulin |
E5 | selected from the group G1 | long-acting insulin |
E6 | selected from the group G1 | selected from the group G2 |
E7 | selected from the group G1 | L1 |
E8 | selected from the group G1 | L2 |
E9 | selected from the group G1 | L3 |
E10 | selected from the group G1 | L4 |
E11 | selected from the group G1 | L5 |
E12 | selected from the group G1 | L6 |
E13 | selected from the group G1 | L7 |
E14 | selected from the group G1a | insulin |
E15 | selected from the group G1a | rapid-acting or short-acting insulin |
E16 | selected from the group G1a | human insulin |
E17 | selected from the group G1a | intermediate-acting or longacting insulin |
E18 | selected from the group G1a | long-acting insulin |
E19 | selected from the group G1a | selected from the group G2 |
E20 | selected from the group G1a | L1 |
E21 | selected from the group G1a | L2 |
E22 | selected from the group G1a | L3 |
E23 | selected from the group G1a | L4 |
E24 | selected from the group G1a | L5 |
E25 | selected from the group G1a | L6 |
E26 | selected from the group G1a | L7 |
E27 | Compound (I.9) | insulin |
E28 | Compound (I.9) | rapid-acting or short-acting insulin |
E29 | Compound (I.9) | human insulin |
E30 | Compound (I.9) | intermediate-acting or longacting insulin |
E31 | Compound (I.9) | long-acting insulin |
E32 | Compound (I.9) | selected from the group G2 |
E33 | Compound (I.9) | L1 |
E34 | Compound (I.9) | L2 |
E35 | Compound (I.9) | L3 |
E36 | Compound (I.9) | L4 |
E37 | Compound (I.9) | L5 |
E38 | Compound (I.9) | L6 |
E39 | Compound (I.9) | L7 |
Among the combinations according to the présent invention listed in Table 1, the combination according to the entries E27 to E39 are even more preferred.
According to a further embodiment the pharmaceutical compositions, methods and uses according to the présent invention relate to a combination of a SGLT2 inhibitor and an insulin which additionally comprises a further antidiabetic agent. Preferred sub-embodiments are selected from the entries F1 to F72 in the Table 2.
Table 2
Embodiment | SGLT2 Inhibitor | Insulin | Further antidiabetic agent |
F1 | selected from the group G1 | insulin | metformin |
F2 | selected from the group G1 | rapid-acting or shortacting insulin | metformin |
F3 | selected from the group G1 | human insulin | metformin |
F4 | selected from the group | intermediate-acting or | metformin |
G1 | long-acting insulin | ||
F5 | selected from the group G1 | selected from the group G2 | metformin |
F6 | selected from the group G1a | insulin | metformin |
F7 | selected from the group G1a | rapid-acting or shortacting insulin | metformin |
F8 | selected from the group G1a | human insulin | metformin |
F9 | selected from the group G1a | intermediate-acting or long-acting insulin | metformin |
F10 | selected from the group G1a | long-acting insulin | metformin |
F11 | selected from the group G1a | selected from the group G2 | metformin |
F12 | Compound (I.9) | insulin | metformin |
F13 | Compound (I.9) | rapid-acting or shortacting insulin | metformin |
F14 | Compound (I.9) | human insulin | metformin |
F15 | Compound (I.9) | intermediate-acting or long-acting insulin | metformin |
F16 | Compound (I.9) | long-acting insulin | metformin |
F17 | Compound (I.9) | selected from the group G2 | metformin |
F18 | Compound (I.9) | L1 | metformin |
F19 | Compound (I.9) | L2 | metformin |
F20 | Compound (I.9) | L3 | metformin |
F21 | Compound (I.9) | L4 | metformin |
F22 | Compound (I.9) | L5 | metformin |
F23 | Compound (I.9) | L6 | metformin |
F24 | Compound (I.9) | L7 | metformin |
F25 | selected from the group G1 | insulin | pioglitazone |
F26 | selected from the group G1 | rapid-acting or shortacting insulin | pioglitazone |
F27 | selected from the group G1 | human insulin | pioglitazone |
F28 | selected from the group G1 | intermediate-acting or long-acting insulin | pioglitazone |
F29 | selected from the group G1 | selected from the group G2 | pioglitazone |
F30 | selected from the group G1a | insulin | pioglitazone |
F31 | selected from the group G1a | rapid-acting or shortacting insulin | pioglitazone |
F32 | selected from the group G1a | human insulin | pioglitazone |
F33 | selected from the group G1a | intermediate-acting or long-acting insulin | pioglitazone |
F34 | selected from the group G1a | long-acting insulin | pioglitazone |
F35 | selected from the group G1a | selected from the group G2 | pioglitazone |
F36 | Compound (I.9) | insulin | pioglitazone |
F37 | Compound (I.9) | rapid-acting or shortacting insulin | pioglitazone |
F38 | Compound (I.9) | human insulin | pioglitazone |
F39 | Compound (I.9) | intermediate-acting or long-acting insulin | pioglitazone |
F40 | Compound (I.9) | long-acting insulin | pioglitazone |
F41 | Compound (I.9) | selected from the group G2 | pioglitazone |
F42 | Compound (I.9) | L1 | pioglitazone |
F43 | Compound (I.9) | L2 | pioglitazone |
F44 | Compound (I.9) | L3 | pioglitazone |
F45 | Compound (I.9) | L4 | pioglitazone |
F46 | Compound (I.9) | L5 | pioglitazone |
F47 | Compound (I.9) | L6 | pioglitazone |
F48 | Compound (I.9) | L7 | pioglitazone |
F49 | selected from the group G1 | insulin | linagliptin |
F50 | selected from the group G1 | rapid-acting or shortacting insulin | linagliptin |
F51 | selected from the group G1 | human insulin | linagliptin |
F52 | selected from the group G1 | intermediate-acting or long-acting insulin | linagliptin |
F53 | selected from the group G1 | selected from the group G2 | linagliptin |
F54 | selected from the group G1a | insulin | linagliptin |
F55 | selected from the group G1a | rapid-acting or shortacting insulin | linagliptin |
F56 | selected from the group G1a | human insulin | linagliptin |
F57 | selected from the group G1a | intermediate-acting or long-acting insulin | linagliptin |
F58 | selected from the group G1a | long-acting insulin | linagliptin |
F59 | selected from the group G1a | selected from the group G2 | linagliptin |
F60 | Compound (I.9) | insulin | linagliptin |
F61 | Compound (I.9) | rapid-acting or shortacting insulin | linagliptin |
F62 | Compound (I.9) | human insulin | linagliptin |
F63 | Compound (I.9) | intermediate-acting or long-acting insulin | linagliptin |
F64 | Compound (I.9) | long-acting insulin | linagliptin |
F65 | Compound (I.9) | selected from the group G2 | linagliptin |
F66 | Compound (I.9) | L1 | linagliptin |
F67 | Compound (I.9) | L2 | linagliptin |
F68 | Compound (I.9) | L3 | linagliptin |
F69 | Compound (I.9) | L4 | linagliptin |
F70 | Compound (I.9) | L5 | linagliptin |
F71 | Compound (I.9) | L6 | linagliptin |
F72 | Compound (I.9) | L7 | linagliptin |
The combination of an SGLT2 inhibitor and an insulin according to this invention significantly improves the glycémie control, in particular in patients as described hereinafter, compared with a monotherapy using either a SGLT2 inhibitor or an insulin alone, for example with a 5 monotherapy of a long-acting insulin, such as insulin glargine. Furthermore the combination of an SGLT2 inhibitor and an insulin according to this invention allows a réduction of the dose of the insulin compared with a monotherapy of said insulin, for example with a monotherapy of a long-acting insulin, such as insulin glargine. With a réduction of the dose of the insulin any side effects associated with the therapy using said insulin may be prevented 10 or attenuated. A dose réduction is bénéficiai for patients which otherwise would potentially suffer from side effects in a therapy using a higher dose of one or more of the active ingrédients, in particular with regard to side effect caused by the insulin. Therefore, the pharmaceutical composition as well as the methods according to the présent invention, show less side effects, thereby making the therapy more tolerable and improving the patients 15 compliance with the treatment In addition the efficacy of the insulin, for example in a basal insulin therapy with a long acting insulin or with a short- or rapid acting insulin, including human insulin, via infusion with a pump, may be prolonged by a combined treatment with a SGLT-2 inhibitor. Therefore the time interval between two applications, for example
-37subcutaneous injections or infusions via a pump, of the insulin may be prolonged. For example in a combination therapy employing a long acting insulin and a SGLT2 inhibitor according to the invention the dose of the long acting insulin, the dose of the SGLT2 inhibitor, the time intervall between two applications of the long acting insulin and the time intervall 5 between the application of the long acting insuin and the SGLT2 inhibitor are chosen such that a good glycémie control is provided to the patient for a given time period, in particular for 24 hours.
When this invention refers to patients requiring treatment or prévention, it relates primarily to _______________*1 /T________r**»*#Sx ZJtrttrrSr*! »·*> Κι i « i« ,l c»lu piovcuuuii.....uiucuis, um ιι ια piιαι11iquouuvai MWinpvoiuvn may aiou ua^3KS**'nA* accordingly In veterinary medlclne in mammals. In the scope of this invention the term patient covers adult humans (âge of 18 years or older), adolescent humans (âge 10 to 17 years) and chlldren (âge 6-9 years).
Furthermore. the method and/or use according to this Invention Is advantageously applicable in those patients who show one, two or more ofthe following conditions:
(a) type 1 diabètes mellitus;
(b) need for treatment with Insulin;
(c) latent autoimmune diabètes with onset in adults (LADA).
Furthermore, the method and/or use according to this invention is advantageously applicable In those patients who are or shall be treated with a insulin, for example with Insulin glarglne or detemlr Insulin, In particular in patients diagnosed with type 1 diabètes mellitus, and show one, two or more of the following conditions, including the risk to develop such conditions:
(d) nocturnal and/or early moming hypoglycémie;
(e) hypoglycémie épisodes;
(f) hyperglycémie épisodes;
(g) cardiac or cérébral complications;
(h) retinopathy, In particular proliférative retinopathy;
(I) Injection site réactions, for example skin or subcutaneous tissue dlsorders.
As described herelnbefore by the administration of the pharmaceutical composition according to this invention and in particular in view of the high SGLT2 Inhibitory activity of the
SGLT2 inhibitors therein, excessive blood glucose is excreted through the urine of the patient, so that less or no gain in weight or even a réduction in body weight may result.
Therefore, a treatment or prophylaxie according to this invention is advantageously suitable
In those patients in need of such treatment or prophylaxis who are diagnosed of one or more ofthe conditions selected from thegroup consisting of overweight and obesity, in particular
-38class I obesity, class II obesity, class III obesity, viscéral obesity and abdominal obesity. In addition a treatment or prophylaxie according to this invention is advantageously suitable in those patients in which a weight increase is contraindicated. Any weight increasing effect in the therapy, for example due to the administration of the third antidiabetic agent, may be attenuated or even avoided thereby.
Therefore, according to a preferred embodiment of the présent invention, there is provided a method for improving glycémie control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c in a patient in need thereof who is diagnosed with impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG) with insulin résistance, with metabolic syndrome and/or with type 1 diabètes mellitus or type 2 diabètes mellitus characterized in that an SGLT2 înhibitor and an insulin as defined hereinbefore and hereinafter are administered, for example in combination or alternation, to the patient.
According to another preferred embodiment of the présent invention, there is provided a method for improving gycemic control in patients, în particular in adult patients, with type 1 or type 2 diabètes mellitus as an adjunct to diet and exercise.
It can be found that by using a pharmaceutical composition according to this invention, an improvement of the glycémie control can be achieved even in those patients who have insufficient glycémie control in particular despite treatment with an insulin, for example despite maximal recommended or tolerated dose of monotherapy with the insulin.
Furthermore, the pharmaceutical composition, the methods and uses according to this invention are particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions (a) obesity (including class I, Il and/or III obesity), viscéral obesity and/or abdominal obesity, (b) triglycéride blood level a 150 mg/dL, (c) HDL-cholesterol blood level < 40 mg/dL in female patients and < 50 mg/dL in male patients, (d) a systolic blood pressure a 130 mm Hg and a diastolic blood pressure £ 85 mm Hg, (e) a fasting blood glucose level & 100 mg/dL.
It is assumed that patients diagnosed with impaired glucose tolérance (IGT), impaired fasting blood glucose (IFG), with insulin résistance and/or with metabolic syndrome sufferfrom an increased risk of developing a cardiovascular disease, such as for example myocardial νΛ infarction, coronary heart disease, heart insufficiency, thromboembolie events. A glycémie control according to this invention may resuit in a réduction of the cardiovascular risks. Furthermore, the pharmaceutical composition, the methods and uses according to this invention are particularly suitable in the treatment of patients after organ transplantation, in particular those patients who are diagnosed having one or more of the following conditions (a) a higher âge, in particular above 50 years, (b) male gender;
(c) overweight, obesity (including class I, Il and/or III obesity), viscéral obesity and/or abdominal obesity, (d) pre-transplant diabètes, (e) immunosuppression therapy.
Furthermore, the pharmaceutical composition, the methods and the uses according to this invention are particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions:
(a) hyponatremia, in particular chronical hyponatremia;
(b) water intoxication;
(c) water rétention;
(d) plasma sodium concentration below 135 mmol/L.
Furthermore, the pharmaceutical composition, the methods and uses according to this invention are particularly suitable in the treatment of patients who are diagnosed having one or more of the following conditions:
(a) high sérum uric acid levels, in particular greater than 6.0 mg/dL (357 pmol/L);
(b) a history of gouty arthritis, in particular récurrent gouty arthritis;
(c) kidney stones, in particular récurrent kidney stones;
(d) a high propensity for kidney stone formation.
A pharmaceutical composition according to this invention, in particular due to the SGLT2 inhibitor exhibits a good safety profile. Therefore, a treatment according to this invention is advantageous in those patients for which a réduction of the dose of the insulin is recommended.
A pharmaceutical composition according to this invention is particularly suitable in the long term treatment or prophylaxis of the diseases and/or conditions as described hereinbefore and hereinafter, in particular in the long term glycémie control in patients with type 1 diabètes mellitus or type 2 diabètes mellitus. -æ/
-40The term long term as used hereinbefore and hereinafter indicates a treatment of or administration in a patient within a period of time longer than 12 weeks, preferably longer than 25 weeks, even more preferably longer than 1 year.
Therefore, a particularly preferred embodiment of the présent invention provides a method for therapy, preferably oral therapy, for improvement, especially long term improvement, of glycémie control in patients with type 1 diabètes mellitus.
Therefore, a particularly preferred embodiment of the présent invention provides a method for therapy, preferably oral therapy, for improvement, especially long term improvement, of glycémie control in patients with type 2 diabètes mellitus, especially in patients with late stage type 2 diabètes mellitus, in particular in patients additionally diagnosed of overweight, obesity (including class I, class II and/or class III obesity), viscéral obesity and/or abdominal obesity.
Unless otherwise noted, the combination therapy according to the invention may refer to first line, second line or third line therapy, or initial or add-on combination therapy or replacement therapy.
According to one embodiment the SGLT2 inhibitor and the insulin and optionally the further antidiabetic agent are administered in combination, i.e. simultaneously, for example in one single formulation or in two separate formulations or dosage forms, or in alternation, for example successîvely in two or three separate formulations or dosage forms. Hence, the administration of one combination partner, i.e. the SGLT2 inhibitor or the insulin, may be prior to, concurrent to, or subséquent to the administration of the other combination partner. In one embodiment, for the combination therapy according to this invention the SGLT2 inhibitor and the insulin are administered in different formulations or different dosage forms. In another embodiment, for the combination therapy according to this invention the SGLT2 inhibitor and the insulin are administered in the same formulation or in the same dosage form.
Therefore according to an embodiment of the présent invention there is provided a pharmaceutical composition or fixed dose combination comprising
a) a SGLT2 inhibitor as defined herein, and
b) an insulin as defined herein, and, optionally, one or more pharmaceutically acceptable carriers and/or diluents.
-41 Within the scope of the présent invention, the SGLT2 inhibitor is preferably administered orally or by injection, preferably orally. The insulin is preferably administered by injection, preferably subcutaneously, or by infusion, for example with a pump. Other forms of administration are possible and described hereinafter. Preferably the optionally administered other antidiabetic agent is administered orally. In this case the SGLT2 inhibitor and the other antidiabetic agent may be comprised together in one dosage form or in separate dosage forms.
Therefore according to another embodiment the présent invention provides a pharmaceutical composition, delivery system or device for systemic use, in particular for administration by injection or infusion, for example subcutaneous injection or infusion via pump, comprising
a) a SGLT2 inhibitor as defined herein, and, optionally,
b) an insulin as defined herein, and, optionally, one or more pharmaceutically acceptable carriers and/or diluents.
It will be appreciated that the amount of the SGLT2 inhibitor and the insulin and optionally of the further antidiabetic agent according to this invention to be administered to the patient and required for use in treatment or prophylaxis according to the présent invention will vary with the route of administration, the nature and severity of the condition for which treatment or prophylaxis is required, the âge, weight and condition ofthe patient, concomitant médication and will be ultimately at the discrétion of the attendant physician. In general, however, the SGLT2 inhibitor, the insulin and optionally the further antidiabetic agent according to this invention are included in the pharmaceutical composition or dosage form in an amount sufficient that by their administration in combination and/or alternation the glycémie control in the patient to be treated is improved.
For the treatment of hyperuricemia or hyperuricemia associated conditions the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount sufficient that is sufficient to treat hyperuricemia without disturbing the patient’s plasma glucose homeostasis, in particular without inducing hypoglycemia.
For the treatment or prévention of kidney stones the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount sufficient that is sufficient to treat or prevent kidney stones without disturbing the patient’s plasma glucose homeostasis, in particular without inducing hypoglycemia.
For the treatment of hyponatremia and associated conditions the SGLT2 inhibitor according to this invention is included in the pharmaceutical composition or dosage form in an amount u/’-'
-42sufficient that is sufficient to treat hyponatremia or the associated conditions without disturbing the patient's plasma glucose homeostasis, in particular without inducing hypoglycemia.
In the following preferred ranges of the amount of the SGLT2 inhibitor, the insulin and optionally the further antidiabetic agent to be employed in the pharmaceutical composition and the methods and uses according to this invention are described. These ranges refer to the amounts to be administered per day with respect to an adult patient, in particular to a human being, for example of approximately 70 kg body weight, and can be adapted accordingly with regard to an administration 1 or 2 times daily and with regard to other routes of administration and with regard to the âge of the patient. The ranges of the dosage and amounts are calculated for the inidividual active moiety. Advantageously, the combination therapy according to the présent invention utilizes lower dosages of the individual SGLT2 inhibitor, ofthe individual insulin and/or optionally ofthe individual further antidiabetic agent used in monotherapy or used in conventional therapeutics, thus avoiding possible adverse side effects incurred when those agents are used as monotherapies.
In general, the amount of the SGLT2 inhibitor in the pharmaceutical composition, methods and uses according to this invention is preferably in the range from 1/5 to 1/1 of the amount usually recommended for a monotherapy using said SGLT2 inhibitor.
The preferred dosage range of the SGLT2 inhibitor is in the range from 0.5 mg to 200 mg, even more preferably from 1 to 100 mg, most preferably from 1 to 50 mg per day. The oral administration is preferred. Therefore, a pharmaceutical composition may comprise the hereinbefore mentioned amounts, in particular from 1 to 50 mg or 1 to 25 mg. Particular dosage strengths (e.g. per tablet or capsule) are for example 1, 2.5, 5, 7.5, 10, 12.5, 15, 20, 25 or 50 mg of the compound of the formula (I), in particular ofthe compound (I.9), orof dapagliflozin. The application of the active ingrédient may occur one, two or three times a day, preferably once a day.
In general, the amount of the insulin in the pharmaceutical composition, methods and uses according to this invention is preferably in the range from 1/5 to 1/1 of the amount usually recommended for a monotherapy using said long acting insulin.
The insulin Is typically administered by subcutaneous injection, e.g. ranging from twice daily, once daily to once weekly injection. Suitable doses and dosage forms of the insulin may be determined by a person skilled in the art. Blood glucose monitoring is essentiel in ail patients receiving insulin therapy. Doses of a long-acting insulin will be individualized
-43accoring to the response to treatment and obtainment of glycaemic control. Doses are; typically in the range of 10 to 70 units/day. According to the WHO the defined daily dose of insulin is 40 units. Usually long acting insulins are given once daily, either in the morning or in the evening. An SGLT-2 inhibitor could be admînisterd at any of these time points. Type 1 diabètes patients would usually be treated with a multiple daily injection regimen comprising basal insulin, for example a long-acting insulin, and a rapid acting insulin. A typical daily insulin requirement in type 1 diabètes is 40 to 60 units, depending on betacell function, âge, weight, degree of physical activity, eating and drinking. Typically around 40-60% of the total daily insulin requirement would be given as basal insulin, for example with a long-acting insulin.
For example, insulin glargine (Lantus) is administered subcutaneously once a day. Lantus may be administered at any time during the day, but at the same time every day. The dose of Lantus is indîvidualized based on clinical response. A typical starting dose of Lantus in patients with type 2 diabètes who are not currently treated with insulin is 10 units, or altematively 0.2 U/kg, once daily, which should subsequently be adjusted to the patient’s needs. Type 1 diabètes patients would usually be treated with a multiple daily injection regimen comprising basal insulin and rapid acting insulin. A typical daily insulin requirement in type 1 diabètes is 40 to 60 units, depending on beta-cell function, âge, weight, degree of physical activity, eating and drinking. Typically around 40-60% of the total daily insulin requirement would be given as basal insulin; when Lantus is used, the same principle for dosing applies in type 1 diabètes as in type 2 diabètes. Also here, a titration of insulin dosages are needed based on clinical response.
Insulin detemir (Levemir) is administered subcutaneously once or twice a day. For patients treated with Levemir once daily, the dose is preferably administered with the evening meal or at bedtime. For patients who require twice-daily dosing, the evening dose can be administered either with evening meal, at bedtime, or 12 hours after the morning dose. The dose of Levemir is indîvidualized based on clinical response. For insulin-naïve patients with type 2 diabètes who are inadequately controlled on oral antidiabetic drugs, Levemir should be started at a dose of 0.1 to 0.2 Units/kg once-daily in the evening or 10 units once- or twice-daily, and the dose adjusted to achieve glycémie targets. In type 1 diabètes patients would usually be treated with a multiple daily injection regimen comprising basal insulin and rapid acting insulin. A typical daily insulin requirement in type 1 diabètes is 40-60 units, depending on beta-cell function, âge, weight, degree of physical activity, eating and drinking. Typically around 40-60% ofthe total daily insulin requirement would be given as basal insulin; when Levemir is used, the same principle for xpA'
-44dosing applies in type 1 diabètes as in type 2 diabètes. Also here, a titration of insulin dosages are needed based on clinical response.
Furthermore the long acting insulin analogues such as insulin degludec and basal insulin lispro will be developed with a final formulation of U-100 and dosing will be individually adapted for these insulins as well, both in type 1 and type 2 diabètes..
In case the SGLT-2 inhibitor and the insulin are to be combined with a further antidiabetic agent, the dose of the further antidiabetic agent is preferably in the range from 1/5 to 1/1 of the dose usually recommended for a monotherapy using said further antidiabetic agent. Using lower dosages of the individual further antidiabetic agent compared with monotherapy could avoid or minimize possible toxicity and adverse side effects incurred when those agents are used as monotherapies.
With regard to metformin as a preferred further antidiabetic agent metformin is usually given in doses varying from about 500 mg to 2000 mg up to 3000 mg per day using various dosing regimens from about 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or about 300 mg to 1000 mg once, twice or thrice a day, or delayed-release metformin in doses of about 100 mg to 1000 mg or preferably 500 mg to 1000 mg once or twice a day or about 500 mg to 2000 mg once a day. Particular dosage strengths may be 250, 500, 625, 750, 850 and 1000 mg of metformin hydrochloride.
For children 10 to 16 years of âge, the recommended starting dose of metformin is 500 mg given once daily. If this dose fails to produce adéquate results, the dose may be increased to 500 mg twice daily. Further increases may be made in incréments of 500 mg weekly to a maximum daily dose of 2000 mg, given in divided doses (e.g. 2 or 3 divided doses). Metformin may be administered with food to decrease nausea.
With regard to pioglitazone as a preferred further antidiabetic agent a dosage of pioglitazone is usually of about 1-10 mg, 15 mg, 30 mg, or 45 mg once a day.
With regard to linagliptine as a preferred further antidiabetic agent a dosage of linagliptine is usually of about 1-10 mg, for example 1,2.5, 5 or 10 mg once a day.
In the methods and uses according to the présent invention the SGLT2 inhibitor and the insulin are administered in combination or alternation. The term administration in combination means that the active ingrédients are administered at the same time, i.e.
simultaneously, or essentially at the same time. The term administration in alternation
-45means that at first one of the two active ingrédients, i.e. the SGLT2 inhibitor or the insulin, is administered and after a period of time the other active ingrédient, i.e. the insulin or the SGLT2 inhibitor, is administered, i.e. both active ingrédients are administered sequentially. The period of time between the administration of the first and of the second active ingrédient may be in the range from 1 min to 12 hours. The administration which is in combination or in alternation may be once, twice, three times or four times daily, preferably once or twice daily.
A pharmaceutical composition which is présent as a separate or multiple dosage form, preferably as a kit of parts, is useful in combination therapy to flexibly suit the individual therapeutic needs of the patient.
According to a first embodiment a preferred kit of parts comprises (a) a first containment containing a dosage form comprising the SGLT2 inhibitor and at least one pharmaceutically acceptable carrier, and (b) a second containment containing a dosage form comprising the insulin and at least one pharmaceutically acceptable carrier.
According to a second embodiment a preferred kit of parts comprises (a) a first containment containing a dosage form comprising the SGLT2 inhibitor and at least one pharmaceutically acceptable carrier, and (b) a second containment containing a dosage form comprising the insulin and at least one pharmaceutically acceptable carrier, and (b) a third containment containing a dosage form comprising a further antidiabetic agent (for example metformin, pioglitazone or linagliptine) and at least one pharmaceutically acceptable carrier.
According to a third embodiment a preferred kit of parts comprises (a) a first containment containing a dosage form comprising the SGLT2 inhibitor and a further antidiabetic agent and at least one pharmaceutically acceptable carrier, and (b) a second containment containing a dosage form comprising the insulin and at least one pharmaceutically acceptable carrier.
A further aspect of the présent invention is a manufacture comprising the pharmaceutical composition being présent as separate dosage forms according to the présent invention and a label or package insert comprising instructions that the separate dosage forms are to be administered in combination or alternation.
-46According to a first embodiment a manufacture comprises (a) a pharmaceutical composition comprising a SGLT2 inhibitor according to the présent invention and (b) a label or package insert which comprises instructions that the médicament may or is to be administered, for example in combination or alternation, with a médicament comprising an insulin according to the présent invention or with a médicament comprising both a insulin and a further antidiabetic agent according to the présent invention.
According to a second embodiment a manufacture comprises (a) a pharmaceutical composition comprising an insulin according to the présent invention and (b) a label or package insert which comprises instructions that the médicament may or is to be administered, for example in combination or alternation, with a médicament comprising a SGLT2 inhibitor according to the présent invention or with a médicament comprising both a SGLT2 inhibitor and a further antidiabetic agent according to the présent invention.
According to a third embodiment a manufacture comprises (a) a pharmaceutical composition comprising a SGLT2 inhibitor and a further antidiabetic agent according to the présent invention and (b) a label or package insert which comprises instructions that the médicament may or is to be administered, for example in combination or alternation, with a médicament comprising an insulin according to the présent invention.
The desired dose of the pharmaceutical composition according to this invention may conveniently be presented in a once daily or as divided dose administered at appropriate intervals, for example as two, three or more doses per day.
The pharmaceutical composition may be formulated for oral, parentéral (including subcutaneous) or other routes of administration in liquid or solid form. Oral administration of the SGLT2 inhibitor is preferred. The formulations may, where appropriate, be conveniently presented in discrète dosage units and may be prepared by any of the methods well known in the art of pharmacy. Ail methods include the step of bringing into association the active ingrédient with one or more pharmaceutically acceptable carriers, like liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation. Examples of pharmaceutical compositions comprising the SGLT2 inhibitor compound (I.9) are described in WO 2010/092126. Examples of pharmaceutical compositions comprising the SGLT2 inhibitor compound (Ι.9) and linagliptin are described in WO 2010/092124.
The pharmaceutical composition may be formulated in the form of solutions, suspensions, émulsions, tablets, granules, fine granules, powders, capsules, caplets, soft capsules, pills, .j/
-47oral solutions, syrups, dry syrups, chewable tablets, troches, effervescent tablets, drops, fast dissolving tablets, oral fast-dispersing tablets, etc.. Preferably the pharmaceutical composition of the SGLT2 inhibitor is in the form of tablets.
The pharmaceutical composition and the dosage forms preferably comprises one or more pharmaceutical acceptable carriers. Preferred carriers must be acceptable in the sense of being compatible with the other ingrédients of the formulation and not deleterïous to the récipient thereof. Examples of pharmaceutically acceptable carriers are known to the one skilled in the art.
The pharmaceutical composition according to the invention may also be formulated for parentéral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or émulsions in oily or aqueous vehîcles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Altematively, the active ingrédients may be in powder form, obtained by aseptie isolation of stérile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. stérile, pyrogen-free water, before use.
Injectable formulations of the insulin and/or the SGLT2 inhibitor of this invention (particularly for subcutaneous use) may be prepared according to known formulation techniques, e.g. using suitable liquid camers, which usually comprise stérile water, and, optionally, further additives such as e.g. preservatives, pH adjusting agents, buffering agents, isotoning agents, solubility aids and/or tensides or the like, to obtain injectable solutions or suspensions. In addition, injectable formulations may comprise further additives, for example salts, solubility modifying agents or precipitating agents which retard release of the drug(s). In further addition, injectable insulin formulations may comprise insulin stabilizing agents, such as zinc compounds. The component insulin of the combination according to the invention is preferably administered by injection (preferably subcutaneously) or by infusion (for example using a pump or comparable delivery system).
For further details on dosage forms, formulations and administration of SGLT2 inhibitors of this invention and/or insulin of this invention, reference is made to scientific literature and/or published patent documents, particularly to those cited herein.
The pharmaceutical compositions (or formulations) may be packaged in a variety of ways. Generally, an article for distribution includes one or more containers that contain the one or^>/
-48more pharmaceutical compositions in an appropriate form. Tablets are typically packed in an appropriate primary package for easy handling, distribution and storage and for assurance of proper stability of the composition at prolonged contact with the environment during storage. Primary containers for tablets may be bottles or blister packs.
Solutions for injection may be available in typical suitable présentation forms such as vials, cartridges or prefilled (disposable) pens, which may be further packaged.
The article may further comprise a label or package insert, which refers to instructions customarily included in commercial packages of therapeutic products, that may contain information about the indications, usage, dosage, administration, contraïndications and/or warnings concerning the use of such therapeutic products. In one embodiment, the label or package inserts indicates that the composition can be used for any of the purposes described hereinbefore or hereinafter.
The pharmaceutical compositions and methods according to this invention show advantageous effects in the treatment and prévention of those diseases and conditions as described hereinbefore compared with pharmaceutical compositions and methods which comprise only one of the two active ingrédients. Additional advantageous effects may be seen for example with respect to efficacy, dosage strength, dosage frequency, pharmacodynamie properties, pharmacokinetic properties, fewer adverse effects, convenience, compliance, etc..
Methods for the manufacture of SGLT2 inhibitors according to this invention and of prodrugs thereof are known to the one skilled in the art. Advantageously, the compounds according to this invention can be prepared using synthetic methods as described in the literature, including patent applications as cited hereinbefore. Preferred methods of manufacture are described in the WO 2006/120208 and WO 2007/031548. With regard to the preferred compound (I.9) an advantageous crystalline form is described in the international patent application WO 2006/117359 which hereby is incorporated herein in its entirety.
With respect to insulins the methods of synthesis are known to the skilled person and as described in the scientific literature and/ or in published patent documents, particularly in those cited hereinbefore.
The active ingrédients, in particular the insulin and/or the further antidiabetic agent, may be présent in the form of a pharmaceutically acceptable sait. The active ingrédients or a
-49pharmaceutically acceptable sait thereof may be présent in the form of a solvaté such as a hydrate or alcohol adduct.
Any of the above mentioned combinations and methods within the scope of the invention may be tested by animal models known in the art. In the following, in vivo experiments are described which are suîtable to evaluate pharmacologically relevant properties of pharmaceutical compositions and methods according to this invention:
Pharmaceutical compositions and methods according to this invention can be tested in genetically hyperinsulinémie or diabetic animais like db/db mice, ob/ob mice, Zucker Fatty (fa/fa) rats or Zucker Diabetic Fatty (ZDF) rats. In addition, they can be tested in animais with experimentally induced diabètes like HanWistar or Sprague Dawley rats pretreated with streptozotocin.
The effect on glycémie control of the combinations according to this invention can be tested after single dosing of the SGLT2 inhibitor and the insulin alone and in combination in an oral glucose tolérance test in the animal models described hereinbefore. The time course of blood glucose is followed after an oral glucose challenge in overnight fasted animais. The combinations according to the présent invention significantly improve glucose excursion compared to each monotherapy as measured by réduction of peak glucose concentrations or réduction of glucose AUC. In addition, after multiple dosing of the SGLT2 inhibitor and the insulin alone and in combination in the animal models described hereinbefore, the effect on glycémie control can be determined by measuring the HbA1c value in blood. The combinations according to this invention significantly reduce HbA1c compared to each monotherapy.
The possible dose réduction of one or both of the SGLT2 inhibitor and the insulin can be tested by the effect on glycémie control of lower doses of the combinations and monotherapies in the animal models described hereinbefore. The combinations according to this invention at the lower doses significantly improve glycémie control compared to placebo treatment whereas the monotherapies at lower doses do not.
A superior effect of the combination of a SGLT2 inhibitor and a insulin according to the présent invention on beta-cell régénération and neogenesis can be determined after multiple dosing in the animal models described hereinbefore by measuring the increase in pancreatic insulin content, or by measuring increased beta-cell mass by morphometric analysis after immunohistochemical staining of pancreatic sections, or by measuring increased glucosestimulated insulin sécrétion in isolated pancreatic islets.
-50Pharmacoloqical Examples
The following examples show the bénéficiai effect on glycémie control of the combination according to the présent invention.
Example 1a:
The following example shows the bénéficiai effect on glycémie control of the combination of a SGLT2 inhibitor (compound (I.9)) and an insulin (insulin glargine) as compared to the respective monotherapies. Ail experimental protocols concerning the use of laboratory animais were reviewed by a fédéral Ethics Committee and approved by govemmental authorities. Two weeks before the study starts, the rats were pretreated with a single dose of 60 mg/kg i.p. of streptozotocin to induced experimental diabètes, resembling a type 1 diabetic condition. During the study blood glucose was followed over 4 h in male, 3-h fasted Sprague-Dawley rats (CrkCD) with an âge of 8-9 weeks at the start of the study. A pre-dose blood sample was obtained by tail bleed for randomization and blood glucose was measured with a glucometer 30, 60, 90 min and 2, 3, 4 hours after administration of the insulin and/or the SGLT2 inhibitor. At time point 0 min, the animais (n = 4-6 per group) were înjected either with insulin glargine or isotonie NaCl subcutaneously. Simultaneously ail animais received oral administrations of either vehicle alone (0.5% aqueous hydroxyethylcellulose) or this vehicle containing the SGLT2 inhibitor. The data are presented as mean±S.E.M. Statistical comparison was conducted by repeated measures two-way ANOVA (analysis of variance) followed by Bonferroni post tests for group-wise comparisons. A p value < 0.05 was considered to show a statistically significant différence. The resuit is shown in Figure 1a. The term Cpd. A dénotés the SGLT2 inhibitor compound (I.9) at a dose of 10 mg/kg. Insulin glargine was administered at a dose of 1.5 lU/animal. The term Cpd. A + Insulin glargine dénotés the combination of the SGLT2 inhibitor compound (I.9) and insulin glargine at the same doses. P values versus control are indicated by asterisks and p values of the monotherapies versus the combination are indicated by crosses (one symbol, p < 0.05; two symbols, p < 0.01 ; three symbols, p < 0.001 ). Four hours after administration, the SGLT2 inhibitor had reduced blood glucose by 19% versus control, and insulin glargine by 27%. Both treatments did not show statistically significant différences versus control. The combination significantly decreased blood glucose by 53% versus control. The decreased blood glucose in the combination group was significantly different from the SGLT2 inhibitor monotherapy. vs/
-51 Example 1b:
The following example shows the bénéficiai effect on glycémie control of the combination of a SGLT2 inhibitor (compound (I.9)) and an insulin (insulin glargine) as compared to the respective monotherapies. Ail experimental protocols concerning the use of laboratory animais were reviewed by a fédéral Ethics Committee and approved by governmental authorities. Two weeks before the study starts, the rats were pretreated with a single dose of 60 mg/kg i.p. of streptozotocin to induced experimental diabètes, resembling a type 1 diabetic condition. During the study blood glucose was followed over 6 h in male, 3-h fasted Sprague-Dawley rats (Crl:CD) with an âge of 8-9 weeks at the start of the study. A pre-dose blood sample was obtained by tail bleed for randomization and blood glucose was measured with a glucometer 30, 60, 90 min and 2, 3, 4, 5, 6 hours after administration of insulin and/or the SGLT2 inhibitor. At time point 0 min, the animais (n = 4-6 per group) were injected either with insulin glargine or isotonie NaCI subcutaneously. Simultaneously ail animais receîved oral administrations of either vehicle alone (0.5% aqueous hydroxyethylcellulose) or this vehicle containing the SGLT2 inhibitor. The data are presented as mean±S.E.M. Statistical comparison was conducted by repeated measures two-way ANOVA followed by Bonferroni post tests for group-wise comparisons. A p value < 0.05 was considered to show a statistically significant différence. The resuit is shown in Figure 1b. The term Cpd. A dénotés the SGLT2 inhibitor compound (I.9) at a dose of 10 mg/kg. Insulin glargine was administered at a dose of 1.5 lU/animal. The term Cpd. A + Insulin glargine dénotés the combination ofthe SGLT2 inhibitor compound (I.9) and insulin glargine at the same doses. P values versus control are indicated by asterisks and p values of the monotherapies versus the combination are indicated by crosses (one symbol, p < 0.05; two symbols, p < 0.01; three symbols, p < 0.001). Six hours after administration, the SGLT2 inhibitor had reduced blood glucose by 13% versus control, and insulin glargine by 22%. Both treatments did not show statistically significant différences versus control. The combination significantly decreased blood glucose by 49% versus control. The decreased blood glucose in the combination group was significantly different from the SGLT2 monotherapy.
-52Example 2a:
The following example shows the bénéficiai effect on glycémie control of the combination of a SGLT2 inhibitor (compound (I.9)) and a low dose of an insulin (insulin glargine) as compared to a high dose of an insulin (insulin glargine). All experimental protocols concerning the use of laboratory animais were reviewed by a fédéral Ethics Committee and approved by governmental authorities. Two weeks before the study starts, the rats were pretreated with a single dose of 60 mg/kg i.p. of streptozotocin to induced experimental diabètes, resembling a type 1 diabetic condition. During the study blood glucose was followed over 4 h in male, 3-h fasted Sprague-Dawley rats (Crl:CD) with an âge of 8-9 weeks at the start of the study. A pre-dose blood sample was obtained by tail bleed for randomizatîon and blood glucose was measured with a glucometer 30, 60, 90 min and 2, 3, 4 h after administration of the insulin alone or together with the SGLT2 inhibitor. At time point 0 min, the animais (n = 4-6 per group) were injected either with insulin glargine or isotonie NaCI subcutaneously. Simultaneously all animais received oral administrations of either vehicle alone (0.5% aqueous hydroxyethylcellulose) or this vehicle containing the SGLT2 inhibitor. The data are presented as mean±S.E.M. Statistical comparison was conducted by repeated measures two-way ANOVA followed by Bonferroni post tests for group-wise comparisons. A p value < 0.05 was considered to show a statistically significant différence. The resuit is shown in Figure 2a.
Insulin glargine was administered at a dose of 1.5 lU/animal (low-dose) or 6 lU/animal (highdose). The term Cpd. A + low-dose insulin glargine dénotés the combination of the SGLT2 inhibitor at a dose of 10 mg/kg and insulin glargine at a dose of 1.5 lU/animal. P values versus control are indicated by asterisks and p values of the low-dose insulin glargine versus the combination or the high-dose insuline glargine are indicated by crosses (one symbol, p < 0.05; two symbols, p < 0.01; three symbols, p < 0.001). Four hours after administration, the low-dose insuline glargine had reduced blood glucose by 27% versus control without showing statistically significant différence. The combination had decreased blood glucose by 53%, which was in the range of the high-dose insulin glargine with a decrease of 47%. Both treatments were significantly different from the control.
Example 2b:
The following example shows the bénéficiai effect on glycémie control of the combination of a SGLT2 inhibitor (compound (I.9)) and a low dose of an insulin (insulin glargine) as compared to a high dose of an insulin (insulin glargine). All experimental protocols concerning the use of laboratory animais were reviewed by a fédéral Ethics Committee and approved by governmental authorities. Two weeks before the study starts, the rats were pretreated with a single dose of 60 mg/kg i.p. of streptozotocin to induced experimental diabètes, resembling a type 1 diabetic condition. During the study blood glucose was followed over 6 h in male, 3-h fasted Sprague-Dawley rats (Crl:CD) with an âge of 8-9 weeks at the start of the study. A viZ-
-53pre-dose blood sample was obtained by tail bleed for randomization and blood glucose was measured with a glucometer 30, 60, 90 min and 2, 3, 4, 5, 6 h after administration of insulin alone or together with the SGLT2 inhibitor. At time point 0 min, the animais (n = 4-6 per group) were injected either with insulin glargine or isotonie NaCI subcutaneously. Simultaneously ail animais received oral administrations of either vehicle alone (0.5% aqueous hydroxyethylcellulose) or this vehicle containing the SGLT2 inhibitor. The data are presented as mean±S.E.M. Statistical comparison was conducted by repeated measures two-way ANOVA followed by Bonferroni post tests for group-wise compensons. A p value < 0,05 was considered to show a statistically significant différence. The resuit is shown in Figure 2b. Insulin glargine was administered at a dose of 1.5 lU/animal (low-dose) or 6 lU/animal (hîgh-dose). The term Cpd. A + low-dose insulin glargine dénotés the combination of the SGLT2 inhibitor at a dose of 10 mg/kg and insulin glargine at a dose of
1.5 lU/animal. P values versus control are indicated by asterisks and p values of the lowdose insulin glargine versus the combination or the high-dose insuline glargine are indicated by crosses (one symbol, p < 0.05; two symbols, p < 0.01; three symbols, p < 0.001). Six hours after administration, the low-dose insuline glargine had reduced blood glucose by 22% versus control without showîng statistically significant différence. The combination had decreased blood glucose by 49%, which was in the range of the high-dose insulin glargine with a decrease of 44%. Both treatments were signîficantly different from the control. The decreased blood glucose in the combination group did not show a statistically significant différence versus the high-dose insulin glargine group.
Example 3:
The following example shows the bénéficiai effect on glycémie control of a SGLT2 inhibitor (compound (1.9)) sequentially added to an insulin (insulin glargine) as compared to the insulin alone. Ail experimental protocols concerning the use of laboratory animais were reviewed by a fédéral Ethics Committee and approved by governmental authorities. Two weeks before the study starts, the rats were pretreated with a single dose of 60 mg/kg i.p. of streptozotocin to induced experimental diabètes, resembling a type 1 diabetic condition. During the study blood glucose was followed over 8 h in male, non-fasted Sprague-Dawley rats (Crl:CD) with an âge of 8-9 weeks at the start of the study. A pre-dose blood sample was obtained by tail bleed and blood glucose was measured with a glucometer 30, 60, 90 min and 2, 3, 4, 5, 6, 8 h after administration of insulin. At time point 0 min, the animais were injected with insulin glargine (n=10) or isotonie NaCI subcutaneously (n=5). At time point 120 (minutes) the insulin glargine-treated mice were randomized according to blood glucose and separated in 2 groups (n=5 per group). Animais received oral administrations of either vehicle alone (0.5% aqueous hydroxyethylcellulose) or this vehicle containing the SGLT2 inhibitor. The data are presented as mean±S.E.M. Statistical comparison was conducted by repeated measures
-54two-way ANOVA followed by Bonferroni post tests for group-wise comparisons. A p value < 0.05 was considered to show a statistically significant différence. The resuit is shown in Figure 3. Insulin glargine was administered at a dose of 1.5 lU/animal. The term Insuline glargine/ Cpd. A dénotés the combination of insulin glargine at a dose of 1.5 lU/animal and the SGLT2 inhibitor at a dose of 10 mg/kg. P values versus control are indicated by asterisks and p values of the vehicle-treated group versus the animais treated with the SGLT2 inhibitor are indicated by crosses (one symbol, p < 0.05; two symbols, p < 0.01; three symbols, p < 0.001 ). The blood glucose between 2 and 8 hours was significantly decreased by 50% when compared to the vehicle-treated mice.
Example 4:
The following example shows the bénéficiai effect on body fat portion of a SGLT2 inhibitor (compound (I.9)) in combination with an insulin (as an insulin-releasing implant) as compared to the insulin (as an insulin-releasing implant) alone. Ail experimental protocols concerning the use of laboratory animais were reviewed by a fédéral Ethics Committee and approved by governmental authorities. Two weeks before the study starts, Sprague-Dawley rats (Crl:CD) were pretreated with a single dose of 60 mg/kg i.p. of streptozotocin to induced experimental diabètes, resembling a type 1 diabetic condition. Twice a day animais received oral administrations of either vehicle alone (0.5% aqueous hydroxyethylcellulose) or this vehicle contaîning the SGLT2 inhibitior (10 mg/kg). In additionaî groups, 1 or 2 insulin-releasing sticks were implanted subcutaneously in the neck of the rats. The SGLT2 inhibitor was administered to animais without or with 1 insulin implant. On day 27, the body fat was measured using the NMR technique. The data are presented as mean±S.E.M. Statistical comparison was conducted by one-way ANOVA followed by Bonferroni post tests/unpaired ttest for group-wise comparisons. A p value < 0.05 was considered to show a statistically significant différence. The resuit is shown in Figure 4. The term Cpd. A dénotés the SGLT2 inhibitor at a dose of 10 mg/kg. P values versus control are indicated by asterisks and p values of the animais receiving 1 implant versus the combination of 1 implant and the SGLT2 inhibitor (denoted as Cpd. A + 1 Implant) are indicated by crosses (one symbol, p < 0.05; two symbols, p < 0.01; three symbols, p < 0.001). Insulin-releasing implants significantly increased body fat portion (1 implant: +83%; 2 implants: +72%) when compared to controls. The combination of 1 implant and the SGLT2 inhibitor (denoted as Cpd. A + 1 Implant) showed significantly lower body fat when compared to the rats receiving 1 implant alone.
Example 5:
Treating patients with type 1 diabètes with the pharmaceutical composition according to the invention, in addition to producing an acute improvement in the glucose metabolic situation, may contribute to a sustainable well metabolic situation in the long term. This may be ob16387
-55served in patients being treated for a longer period, e.g. 3 months to 1 year or even 1 to 6 years, with the pharmaceutical composition according to the invention and compared with patients who are treated with insulin alone. There is evidence of therapeutic success compared with patients treated with insulin alone if no increase in the fasting glucose and/or
HbA1c value is observed but where a réduction in hypoglycaemia event rate, glucose excursions or insulin requirement is seen. Further evidence of therapeutic success is obtaîned if a significantly smaller percentage of the patients treated with a pharmaceutical composition according to the invention, compared with patients who are treated with optimized insulin alone, undergo a détérioration in the glucose metabolic position (e.g. an increase in the HbA1c value to >6.5% or >7%). For example a clinical study with 30 patients with type 1 diabètes (for example utilizing insulin pumps or receiving a therapy comprising a long-acting insulin) can explore the effect of the SGLT2 inhibitor (in particular the compound (I.9), for example 10 or 25 mg once daily) as an adjunct to insulin with regards to safety and efficacy.
Claims (9)
- Patent Claims:1. A pharmaceutical composition comprising (a) an SGLT2 înhibitor, and (b) an insulin.
- 2. The pharmaceutical composition according to the claim 1 wherein the SGLT2 înhibitor is selected from the group consisting of glucopyranosyl-substituted benzene dérivatives of the formula (I) wherein R1 dénotés Cl, methyl or cyano; R2 dénotés H, methyl, methoxy or hydroxy and R3 dénotés ethyl, cyclopropyl, ethynyl, ethoxy, (R)-tetrahydrofuran-3-yloxy or (S)tetrahydrofuran-3-yloxy; or a prodrug thereof.
- 3. The pharmaceutical composition according to the claim 1 or 2 wherein the insulin is selected from the group consisting of:- rapid-acting insulins,- short-acting insulins,- intermediate-acting insulins,- long-acting insulins, including mixtures thereof.
- 4. The pharmaceutical composition according to the claim 1 or 2 wherein the insulin is a long-acting insulin.
- 5. The pharmaceutical composition according to one of the previous claims characterized în that the composition is suitable for combined or simultaneous or sequential use of the SGLT2 înhibitor and the insulin.
- 6. Use of a SGLT2 inhibitor according to claim 1 or 2 in the manufacture of a médicament for treating a disease or condition selected from the group consisting of diabètes mellitus, type 1 diabètes mellitus, type 2 diabètes mellitus and a disease or condition which requires treatment with insulin in a patient in need thereof, wherein the SGLT2 inhibitor and an insulin are for administration in combination or alternation to the patient.
- 7. Use of an insulin according to claim 1, 3 or 4 in the manufacture of a médicament for treating a disease or condition selected from the group consisting of diabètes mellitus, type 1 diabètes mellitus, type 2 diabètes mellitus and a disease or condition which requires treatment with insulin in a patient in need thereof, wherein a basal insulin therapy and a SGLT2 inhibitor are for administration to the patient
- 8. Use of a pharmaceutical composition according to one of the claims 1 to 5 in the manufacture of a médicament for treating diabètes mellitus;treating diabètes mellitus, where treatment with insulin is required; treating type 1 diabètes mellitus;treating, preventing or reducing the risk of hypoglycemia;preventing, slowing progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus; preventing, slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 1 diabètes mellitus, type 2 diabètes mellitus, impaired glucose tolérance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, overweight, obesity, metabolic syndrome, gestational diabètes, diabètes related to cystic fibrosis; or improving glycémie control and/or for reducing of fasting plasma glucose, of postprandial plasma glucose and/or of glycosylated hemoglobin HbA1c; or preventing, slowing, delaying or reversing progression from impaired glucose tolérance, insulin résistance and/or from metabolic syndrome to type 2 diabètes mellitus; or preventing, slowing the progression of, delaying or treating of a condition or disorder selected from the group consisting of complications of diabètes mellitus such as cataracts and micro- and macrovascular diseases, such as nephropathy, retinopathy, neuropathy, tissue ischaemia, diabetic foot, arteriosclerosis, myocardial infarction, accute coronary syndrome, unstable angina pectoris, stable-58angina pectoris, stroke, peripheral arterial occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders and vascular restenosis; or reducing body weight and/or body fat or preventing or attenuating an increase in body weight and/or body fat or facilitating a réduction in body weight and/or body fat; or preventing, slowing, delaying or treating the degeneration of pancreatîc beta cells and/or the décliné of the functionality of pancreatîc beta cells and/or for improving and/or restoring the functionality of pancreatîc beta cells and/or restoring the functionality of pancreatic insulin sécrétion; or for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat; or maintaining and/or improving the insulin sensitivity and/or for treating or preventing hyperinsulinemia and/or insulin résistance;preventing, slowing progression of, delaying, or treating new onset diabètes after transplantation (NODAT) and/or post-transplant metabolic syndrome (PTMS); preventing, delaying, or reducing NODAT and/or PTMS associated complications including micro- and macrovascular diseases and events, graft rejection, infection, and death;treating hyperuricemia and hyperuricemia associated conditions;treating or preventing kidney stones;treating hyponatremia;in a patient in need thereof.
- 9. Use according to one of the claims 6, 7 or 8 wherein the patient is an individual diagnosed of one or more of the conditions selected from the group consisting of overweight, obesity, viscéral obesity and abdominal obesity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10190303.7 | 2010-11-08 | ||
EP11151059.0 | 2011-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16387A true OA16387A (en) | 2015-10-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220152159A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20170305952A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
US20230285432A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
EP2986304B1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
CA2812016A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
OA16387A (en) | Pharmaceutical composition, methods for treating and uses thereof. |